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ABSTRACT 
Background: Cancer patients undergoing chemotherapy often experience chemotherapy-
induced-peripheral-neuropathy, which reportedly causes gait disturbances that may increase their 
risk for falls.  Falls are a significant event because they have been linked to serious injuries and 
disabilities, loss of independence, and increased mortality rates.  Purpose: The purpose of this 
study was to assess whether chemotherapy-induced peripheral neuropathy is associated with 
spatiotemporal gait adaptations in posttreatment adult cancer survivors when compared to 
healthy, disease-free, age and morphologically matched controls.  Methods: In a quasi-
experimental design, 16 subjects participated in the present study.  There were 8 CIPN subjects 
between the ages of 50–70 years of age who had a histologically confirmed stage 2–3 breast or 
colorectal cancer diagnosis with a confirmed treatment plan consisting of taxane- or oxaliplatin-
based chemotherapy.  Controls consisted of 8 age and morphologically matched subjects.  The 
primary outcome consisted of spatiotemporal gait parameters as computed using the GAITRite 
walkway and software.  Secondary outcomes consisted of determining fall risk using the Timed 
Up & Go test.  Results: Gait velocity for CIPN patients (110. 75 cm/s, SD = 26.79), was 
significantly slower than gait velocity of the controls (147.79 cm/s, SD = 11.69).  Step length 
was significantly shorter for CIPN (53.92 cm, SD = 23.55) when compared to the controls (77.15 
cm, SD = 5.28).  Lastly, CIPN participants had a significantly higher TUG Score (12.33 s, SD 
6.25) compared to the controls (6.62 s, SD = 1.10).  Conclusion: Cancer patients with CIPN 
displayed a slower walking velocity and shorter step length compared to healthy age and 
morphologically matched controls.  Additional gait patterns, such as step time, step length, base 
of support, swing time, single support time, and double support time, were not significantly 
different.   Also, the mean TUG score for CIPN patients were not only significantly greater than 
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the controls, but were also above the clinical fall risk cut off of 10.7 s, indicating fall risk. While 
gait speed and step length were the only significant gait variables, as noted in the literature they 
are key indicator for fall risk. 
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Chapter I 
INTRODUCTION 
Chemotherapy-induced peripheral neuropathy (CIPN) is generally classified as a series of 
neuromuscular symptoms, both sensory and motor in nature, that results from nerve damage 
caused by the neurotoxic effects of chemotherapy drugs for the treatment of cancer (Park et al., 
2013; Visovsky, 2003).  It is estimated that at least 30% of patients who receive paclitaxel, 
docetaxel, bortezomib, thalidomide, or oxaliplatin will develop a degree of chemotherapy-
induced peripheral neuropathy.  The characteristics of CIPN depend upon the specific 
chemotherapy agent used, as well as when the agent is introduced in the treatment protocol and 
the dosage amount (Airley, 2009).   
Symptoms of CIPN may be acute, mild or severe, transient or chronic, depending upon 
the treatment regime and dose of the agents and may manifest in a variety of ways, involving 
sensory and motor symptoms (Park et al., 2013; Postma & Heimans, 2000; Wilkes, 2007).  
Sensory signs and symptoms may include numbness, tingling, burning, pain, ataxia, loss of deep 
tendon reflex, and reduced sense of touch, vibration, and proprioception.  Motor symptoms may 
include weakness, balance disturbances, and difficulty performing fine motor skills and a 
diminished or absent deep tendon reflex.  Motor symptoms are less frequent due to the 
neurotoxic agent’s inability to cross the blood–brain barrier in concentrations significant to cause 
harm (Bakitas, 2007; Murillo, Cox, & Oholendt, 2008; Park et al., 2013; Visovsky, Collins, 
Abbott, Aschenbrenner, & Hart, 2007; Wilkes, 2007).  The autonomic system may also be 
affected, resulting in constipation, urinary retention, sexual dysfunction, and altered blood 
pressure (Bakitas, 2007; Visovsky et al., 2007; Wilkes, 2007).   
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Sensory changes in the toes and feet are usually first to be noticed, followed by in the 
fingers and hands, progressing in a distal–proximal fashion to the ankles and wrist in a stocking-
glove manner (Park et al., 2013; Wolf, Barton, Kottschade, Grothey, & Loprinzi, 2008).  
Chemotherapy-induced peripheral neuropathy symptoms are most commonly distributed in a 
bilateral and symmetrical pattern.  It is not uncommon for CIPN symptoms to intensify after the 
neurotoxic agent has been discontinued; this is referred to as coasting and is the result of 
cumulating concentrations of the neurotoxic agent within the body system.  In some instances, 
CIPN symptoms may occur gradually over a prolonged period.  But it is not uncommon for 
CIPN symptoms to appear suddenly and intensely (Wilkes, 2007).    
The impact of CIPN varies and, thus, affects patients differently.  Cumulatively, CIPN 
symptoms may negatively alter a patient’s ability to perform routine activities, functions, and 
behaviors.  Specifically, patients experiencing CIPN symptoms will often report difficulties such 
as with sleeping, driving, standing, walking, climbing stairs, balancing, opening containers, 
holding onto things, cooking, cleaning, flipping pages of paper, wearing certain shoes and 
jewelry, exercising, and socializing (Speck et al., 2012; Tofthagen, 2010).  The most common 
symptoms reported include burning, muscle aches, and sensitivity to cold (Tofthagen, 2010).  
Patients with CIPN reported a variety of symptoms in their feet, which included the feelings of 
“ice cold,” “walking on hot coals,” and “sandpaper on the bottom of your feet” (Tofthagen, 
2010, p. E25).    
The exact cause of CIPN remains elusive.  However, it is currently understood that 
chemotherapy agents will often inflict their neurotoxic effects on axons and cell bodies of dorsal 
root ganglion neurons, resulting in axonal damage, which is characterized by a decrease in 
intraepidermal nerve fiber density and terminal arbor degeneration (Han & Smith, 2013).   
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Chemotherapy agents will also exert their toxicity on mitochondria, causing them to 
become swollen and vacuoled, as well as causing oxidative stress, resulting in inflammation.  
Pathologically, the dorsal root ganglion neurons and surrounding satellite cells may negatively 
alter the expression of various ion channels, neurotransmitters, and receptors, as well as exhibit 
altered gene expression.  The mitochondrial dysfunction and IENF loss seem to be directly 
correlated to presence of pain.  Cumulatively, these changes cause various sensory symptoms, 
such as numbness, tingling, burning, pain, and reduced sense of touch, as well as motor 
symptoms, such as weakness, balance disturbances, and difficulty performing fine motor skills, 
as frequently reported by cancer patients undergoing chemotherapy treatment (Bakitas, 2007; 
Han & Smith, 2013; Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007). 
Although the mechanism that causes CIPN is not well understood, it is apparent that 
chemotherapy agents will exert their neurotoxic effects on the body’s neurons, which is the basic 
component of the nervous system, and transmit signals throughout the body.  Neurons have three 
functional classes, which include sensory neurons (also called afferent neurons), motor neurons 
(also called efferent neurons) and interneurons, which originate and terminate in the brain or 
spinal cord, acting as connections between axons descending and descending within the brain or 
spinal cord (Magill & Anderson, 2013).  Sensory neurons send neural impulses to the central 
nervous system (CNS), whereas motor neurons send neural impulses from the CNS to skeletal 
muscle fibers (Magill & Anderson, 2013).   
The peripheral nervous system has three functional divisions, which are the sensory 
nerves, motor nerves, and the autonomic nerves.  The sensory nerves sense touch, pain, 
temperature, position, and vibration.  The motor nerves are responsible for voluntary movement, 
muscle tone, and coordination (Armstrong, Almadrones, & Gilbert, 2005).  The small nerve 
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fibers are primarily composed of microtubules, which transport proteins throughout the nerve 
fiber.  Large nerve fibers are primarily composed of neurofilaments, which comprise the axon’s 
framework.  Sensory nerves terminate at the level of the skin and extend to the dorsal root 
ganglion, connecting with either the dorsal column via a large fiber or the spinothalamic tract via 
a small fiber in the spinal cord (Armstrong et al., 2005). 
The somatosensory system, which consists of muscle spindles, Golgi tendon organs, joint 
receptors, and cutaneous receptors, contributes the modulation of spinal pattern generators, 
modulation of motor commands, and perception and control of movement through sensory 
information.  These sensory neurons provide information about mechanical stimuli, temperature 
changes, potential damage to the skin, body and limb movement and position, and velocity and 
muscle activation (Magill & Anderson, 2013; Shumway-Cook & Woollacott, 2012).  Of 
particular interest are cutaneous receptors, which consist of mechanoreceptors, thermoreceptors, 
and nociceptors, and are located within sensitive areas of the skin with as many as 25,000 per 
square centimeter (Shumway-Cook & Woollacott, 2012).  Cutaneous sensory receptors provide 
information about the body’s orientation within the immediate environment and provide 
information necessary for reflexive responses.   
Cumulatively, sensory receptors within the somatosensory system provide information 
via afferent nerve fibers to the spinal cord, which allows for the modulation of locomotion.  
Control of one’s gait may also depend upon afferent information from additional sources, 
including the visual, vestibular, and proprioceptive systems (Dietz, 2002; Gandevia & Burke, 
1992).   
Gait has been defined as a subconscious and highly reproducible movement, that is often 
performed daily as one participates in their daily activities.  Stable gait requires appropriate 
EFFECTS OF CIPN ON GAIT AND FALL RISK                                                                    15  
communication between the neuronal spinal and supraspinal pattern generators, as well as 
sensory feedback from visual, vestibular, and proprioceptor systems.  Feedback from the sensory 
system is believed to provide critical information for the adjustment of stride-to-stride limb 
trajectories in order to smooth out unintended irregularities during walking (Dietz, 2002).  
Therefore, peripheral sensibility is often reduced in individuals with peripheral neuropathy, 
which may negatively affect proprioceptive feedback, thus disrupting normal locomotion and 
increased variability in one’s gait (Wuehr et al., 2014).  
Although it has been well documented that cancer survivors who are undergoing or have 
undergone chemotherapy may experience peripheral neuropathy and gait disturbances, research 
regarding the exact changes that have occurred in their gait cycle and cause patients to report 
unsteady gait and frequent calls are relatively new and unknown.  Alternatively, the effects that 
peripheral neuropathy has on gait has been well documented within the diabetic population.  
Specifically, it has been demonstrated that individuals with diabetic peripheral neuropathy 
generally display a gait that is more conservative and may be characterized by slower walking 
velocities and smaller step sizes (Paul, Ellis, Leese, McFadyen, & McMurray, 2009; Wrobel, 
Crews, & Connolly, 2009).  Similar to chemotherapy-induced peripheral neuropathy (CIPN), 
diabetic peripheral neuropathy (DPN) targets both sensory and motor fibers and is progressive in 
nature.  Large and small diameter nerve fibers are affected, resulting in attenuated sensory nerve 
conduction, which includes large fiber thresholds for vibration and joint positions, as well as 
neurogenic atrophy due to axonal degeneration of motor fibers (Andersen, Gadeberg, Brock, & 
Jakobsen, 1997; Dyck & Thomas, 1999; Horak, Dickstein, & Peterka, 2002) 
Individuals with DPN often display altered gait patterns, which may be characterized as 
slower, with shortened stride lengths and increased base widths, stride times, and double support 
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times when compared to age-matched controls (Andersen et al., 1997; Dyck & Thomas, 1999; 
Horak et al., 2002; Shankarappa, Piedras-Rentería, & Stubbs, 2011; Wuehr et al., 2014). 
Furthermore, individuals with peripheral neuropathy often display significant increases in 
locomotor variability. Not surprising, increased variability in the gait cycle has been found to be 
most correlated with falls (Dingwell & Cavanagh, 2001).   
Although research indicates that sensory feedback plays a critical role in adjusting the 
stride-to-stride limb trajectories in order to smooth out irregularities during unperturbed 
movements and safely navigate and maintain balance, when the somatosensory system is 
compromised, as in the case of peripheral neuropathy, increased variability arises.  Previous 
research indicates that increased stride-to-stride variability associated with one’s  stride length, 
walking speed, and double support time  each independently contribute to falling (Dingwell & 
Cavanagh, 2001; Gandevia & Burke, 1992; Maki, 1997) 
Falling is a significant event, especially for older adults, as falls have been linked to 
serious injuries and disabilities, loss of independence, and increased mortality.  Twenty-three 
percent of falls in adults aged 65–69 result in death, with the rate climbing as high as 50% of 
falls resulting in death for adults aged 85 or older.  It is estimated that of the 1.6 million new 
cancer diagnoses in 2013, 77% were individuals over the age of 55 (Alamgir, Muazzam, & 
Nasrullah, 2012).  Cancer patients experiencing peripheral neuropathy have reported difficulties 
in walking and incidences of falls (Tofthagen, Visovsky, & Berry, 2012).  In fact, it’s estimated 
quantified that approximately 20% of patients with CIPN may fall, which is a higher percentage 
than age-matched controls (Mohile et al., 2009, 2011; Tofthagen, Overcash, & Kip, 2012).  
Stone and colleagues (2012) conducted a 6-month prospective study of cancer patients and found 
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that 50.3% of the patients fell during the studies follow-up period.  More significantly, over one-
third of the falls resulted in soft tissue injuries and 3.2% resulted in fractures. 
Early research suggests that cancer patients may experience axonopathy and a 
compromised somatosensory system as a result of undergoing chemotherapy treatments (Han & 
Smith, 2013; Visovsky & Daly, 2004).  It has been noted that cancer patients experiencing even 
mild peripheral neuropathy after receiving taxane chemotherapy may experience significant 
changes in postural stability as a result of their treatment, which may cause the neurotoxic effect 
of taxane on the somatosensory systems and the subsequent changes that occur as a result of the 
neurotoxicity.  Furthermore, while the severity of the peripheral neuropathy experienced by the 
participants in this study was mild, the postural instability displayed was comparable to diabetic 
individuals diagnosed with severe neuropathy. 
In summary, cancer patients undergoing chemotherapy may often experience varying 
degrees of chemotherapy-induced peripheral neuropathy (CIPN), which may result in impaired 
neuronal function and manifest through a loss of sensation and proprioception, disturbed nerve 
conduction velocities, and a reduction in muscle strength (Argyriou et al., 2013; Bakitas, 2007; 
Krishnan, Goldstein, Friedlander, & Kiernan, 2005; Murillo et al., 2008; Park et al., 2013; 
Visovsky et al., 2007; Wilkes, 2007).  Chemotherapy agents have a toxic effect on the 
somatosensory component of the nervous system (Stillman & Cata, 2006; Wang, Lehky, Brell, & 
Dorsey, 2012; Wickham, 2007).  This facet of the nervous system is responsible for modulating 
and producing coordinated gait patterns. When impaired, it may result in functional impairments 
that lead to walking difficulties, as reported by cancer patients (Shumway-Cook & Woollacott, 
2012). 
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Research indicates that abnormalities or the observation of variability in gait parameters, 
such as cadence, stride length, swing, double support, stride length variability, and swing time 
variability, may increase the risk of falling (Toulotte, Thevenon, Watelain, & Fabre, 2006; 
Verghese, Holtzer, Lipton, & Wang, 2009).  Falling is a significant event for the elderly 
population, as falls have been linked to serious injuries and disabilities, loss of independence, 
and increased mortality (Alamgir et al., 2012).  It is estimated that of the 1.6 million new cancer 
diagnoses in 2013, 77% were individuals over the age of 55, and previous research indicated that 
20% of patients with CIPN may fall, which is a higher percentage than the age-matched 
nondisease control (Alamgir et al., 2012; American Cancer Society, 2013; Mohile et al., 2009, 
2011; Tofthagen et al., 2012). 
Peripheral neuropathy may also be experienced in diabetic patients, and research suggests 
that the symptoms and pathophysiology of diabetic peripheral neuropathy (DPN) are similar to 
cancer patients with CIPN (Andersen et al., 1997; Dyck & Thomas, 1999; Horak et al., 2002; 
Tesfaye & Selvarajah, 2011).  These diabetics display altered gait patterns characterized by 
slower gait velocities, shorter step lengths, and lower cadences, which may be the result of 
altered muscle activation times and velocity, as well as decreased joint mobility (Andersen et al., 
1997; Paul et al., 2009; Savelberg et al., 2010; Sawacha et al., 2009; Thomas & Tomlinson, 
1993). 
Although CIPN is prevalent in cancer patients undergoing chemotherapy, evidence 
suggests that other patient populations, such as diabetics with peripheral neuropathy, may 
experience abnormal spatiotemporal gait patterns due to neuropathic symptoms.  In turn these 
abnormalities may increase the risk of falls, yet surprisingly spatiotemporal gait parameters have 
not been studied in cancer patients undergoing chemotherapy (Wallace et al., 2002). 
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Statement of the Problem 
Chemotherapy agents have a toxic effect on the somatosensory component of the nervous 
system, causing many cancer patients to experience chemotherapy-induced peripheral 
neuropathy, which may be described as loss of sensation and proprioception, disturbed nerve 
conduction velocities, and a reduction in muscle strength (Argyriou et al., 2013; Bakitas, 2007; 
Krishnan et al., 2005; Murillo et al., 2008; Stillman & Cata, 2006; Visovsky et al., 2007; Wang 
et al., 2012; Wickham, 2007; Wilkes, 2007).  This facet of the nervous system is responsible for 
modulating and producing coordinated gait patterns and when impaired may result in functional 
impairments that lead to walking difficulties, as reported by cancer patients (Shumway-Cook & 
Woollacott, 2012).  Diabetics commonly experience peripheral neuropathy.  The presence of 
peripheral neuropathy has been associated with changes in gait patterns and increases in falls in 
this population (Andersen et al., 1997; Paul et al., 2009; Savelberg et al., 2010; Sawacha et al., 
2009; Thomas & Tomlinson, 1993).   Research indicates that abnormalities in gait parameters 
may increase the risk of falling, which is a significant event for the elderly population, as falls 
have been linked to serious injuries and disabilities, loss of independence, and increased 
mortality (Alamgir et al., 2012; Toulotte et al., 2006; Verghese et al., 2009).  Copious amounts 
of research demonstrate the importance of the somatosensory system for gait modulation, and 
when this system is impaired, significant gait changes occur that increase fall risk.  Nonetheless, 
insight into changes in gait patters of cancer patients with CIPN remains unknown.  Considering 
the increased incidence of falls in cancer patients with CIPN, it is paramount to investigate if the 
same gait changes occur within cancer patients as with CIPN.    
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Purpose of the Study 
The purpose of this study was to investigate if changes occur in spatiotemporal gait 
parameters of cancer patients who have undergone taxane- or platinum-based chemotherapy 
treatments and have been diagnosed with chemotherapy-induced peripheral neuropathy.  
Additionally, the level of fall risk associated with the CIPN remains a secondary variable of 
interest. 
Research Question 
1. Do significant changes occur in spatial gait parameters within individuals diagnosed with 
CIPN as a result of undergoing either taxane- or platinum-based chemotherapy agents?  
2. Do significant changes occur in temporal gait parameters within individuals diagnosed 
with CIPN as a result of undergoing either taxane- or platinum-based chemotherapy 
agents?  
3. Does a significant change occur in fall risk within individuals diagnosed with CIPN as a 
result of undergoing either taxane or platinum based chemotherapy agents? 
Hypothesis 
1. There will be significant differences in spatial gait parameters between individuals 
diagnosed with CIPN and age- and morphologically matched controls.  
2. There will be significant differences in temporal gait parameters between individuals 
diagnosed with CIPN and age-and morphologically matched controls.  
3. There will be significant differences in fall risk between individuals diagnosed with CIPN 
and age- and morphologically matched controls. 
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Chapter II 
REVIEW OF THE LITERATURE  
The American Cancer Society (2013) estimated that as of January 1, 2013, there were 
13.7 million Americans living with a history of cancer.  This number is expected to increase, as it 
is estimated that 1,685,210 new cancer cases are expected to be diagnosed in 2013 (Siegel, et al., 
2016).  From 1975 to 1977, an individual diagnosed with cancer had a 49% chance of surviving 
5 years past his or her initial cancer diagnosis.  Today, an individual with a cancer diagnosis has 
a 68% chance of surviving at least 5 years past his or her initial diagnosis (Siegel et al., 2016).  
Given this increased 5-year relative survival rate, it is of paramount importance to address and 
evaluate how a cancer survivor’s quality of life and ability to function are affected by the cancer 
treatment process.   
Cancer is a general term used for a disease that consists of more than 200 various types 
that can occur at any point throughout the lifespan, with different growth rates and abilities to 
spread or metastasize, resulting in varying treatment options and prognoses.  Despite the 
numerous types of cancers, when viewed at the cellular and molecular levels, there are only a 
few variations of cancer based upon alterations in genetics and defective cell functions (Eggert, 
2010).  In global terms, cancer is uncontrolled cell growth and proliferation that develops as a 
result of the accumulation of mutations or genetic abnormalities within a cell.  Genes can 
experience mutations, which cause the cell to increase activity (oncogenes), or mutations, which 
result in a decrease in cellular activity (tumor suppressor genes).  Regardless of the process, the 
result is a nonfunctional cell that will begin to multiply due to its resistance to the normal cell 
signaling process.  The mutated cells, resistant to apoptosis, which is preprogrammed cell death, 
will grow uncontrollably and multiply, forming masses of nonfunctional tissue that will take over 
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the space of functional tissue, ultimately causing various malfunctions that disturb normal 
processes throughout the body (Pecorino, 2008).  
Cancer cells exhibit cellular characteristics that definitively separate them from normal, 
healthy cells.  A primary characteristic that separates cancer cells from normal cells is that cancer 
calls can grow and divide absent of receiving signals from the various environmental and growth 
factors that are normally needed for cells to divide.  Additionally, unlike normal healthy cells, 
cancer cells can ignore growth inhibitory signals.  The ability to ignore these signals may be due 
to mutations that allow cancer cells to short-circuit the growth factor pathways, resulting in 
unchecked and unregulated cell growth (Pecorino, 2008).   
Cancer cells can avoid apoptosis, which is preprogrammed cell death.  Noncancerous 
cells, in response to damage to their DNA or simply as part of the cell cycle, will be destroyed 
and removed by apoptosis.  However, cancer cells have the ability to evade apoptosis signals and 
continue to proliferate (Pecorino, 2008).  Cancer cells also possess unlimited replicative 
potential.  Normal cells contain autonomous counting devices that determine the cell’s finite 
replication potential.  The counting devices are telomeres, which are located at the ends of 
chromosomes.  As cells replicate, the telomeres shorten until they reach a length that halts 
further replicative processes.  However, telomeres of cancer cells are altered and stay a 
consistent length despite constant replication, which allows cancer cells to possess unlimited 
replicative potential (Pecorino, 2008).   
Normal, healthy cells receive oxygen and nutrients from blood vessels.  The number and 
architecture of these blood vessels remain relatively constant.  Cancer cells are able to induce 
angiogenesis, which is the creation of new blood vessels.  This process is important for cancer 
cells as the growth of new blood vessels is needed in order to feed the continuously proliferating 
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tumor.  Lastly, whereas normal cells will remain in relatively the same location throughout their 
life span, cancer cells possess the ability migrate to various other parts of the body, a process 
called metastasis (Pecorino, 2008). 
Treating cancer can be difficult because not all cancer cells behave in the same manner 
(Schneider, Dennehy, & Carter, 2003).  Ultimately, the primary goal of cancer therapies, such as 
chemotherapy and radiation therapy, are to cause cell death.  Traditional cancer treatments 
include chemotherapy, radiation therapy, and surgery, which effectively cause cell death 
(Navarro & Mejı́a Vázquez, 2010).  The goal of these treatments is to achieve and maintain 
remission.   
Additionally, due to the difficulty in destroying cancer cells, many normal cells are 
destroyed in the process, resulting in negative physiological side effects to normal tissues and 
body functions (Courneya & Friedenreich, 2011; Schneider et al., 2003).  Many of the body 
systems, such as the immune system, cardiovascular and pulmonary system, musculoskeletal 
system, and gastrointestinal system, will experience extreme toxicities (Courneya & 
Friedenreich, 2011; Schneider et al., 2003).   
The physiological toxicities to the various bodily system experienced by cancer survivors 
may also have negative effects on their psychosocial well-being and quality of life.  Many cancer 
survivors struggle to cope with physical losses, such as loss of hair or loss of one or both breasts, 
the colon, the jaw, or other body part(s).  Cancer survivors may experience drastic weight 
fluctuations, as well as the development of lymphedema, which is a swelling of an appendage.  
Actual or perceived changes in body image may result in anger and/or depression.  The extent of 
the toxicities and the specific system that is damaged, as well as the extent of the psychological 
disturbances that may accompany actual or perceived physical changes, may depend on the 
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specific therapy utilized, as well as the intensity of that therapy (Courneya & Friedenreich, 2011; 
Schneider et al., 2003).   
Chemotherapy is often used in combination with other treatments, such as surgery or 
radiation, and is a form of drug therapy that causes cellular death (Airley, 2009).  Chemotherapy 
may be administered orally or intravenously and is dispersed in repeated courses over a 3- to 6-
month period.  Chemotherapy drugs work by targeting rapidly dividing cells and disrupting the 
cells’ ability to replicate.  Chemotherapy drugs cannot differentiate between normal, quickly 
dividing cells and cancer cells.  Consequently, noncancer cells are also destroyed in the process.  
For example, hair cells are among those that are rapidly dividing and are often destroyed by 
chemotherapy, resulting in loss of hair by the patient.  The rapidly dividing cells that comprise 
human skin are also affected by chemotherapy drugs, which can routinely produce rashes and 
dry skin.  The cells that line the inside of human guts and mouths divide at a similar rate as 
cancer cells; therefore, chemotherapy typically affects these cells as well, causing various side 
effects such as mouth sores, nausea, vomiting, and fatigue (Airley, 2009). 
Due to the fact that chemotherapy agents will target normal, rapidly diving cells, patients 
undergoing chemotherapy may potentially experience one or more countless side effects.  A 
common side effect of chemotherapy is chemotherapy-induced peripheral neuropathy (CIPN). 
Symptoms of CIPN may be acute, mild or severe, transient or chronic, depending upon 
the treatment regime and the dose of the agents.  They may manifest in a variety of ways, 
involving sensory and motor symptoms (Park et al., 2013; Postma & Heimans, 2000; Wilkes, 
2007).  Sensory signs and symptoms may include numbness, tingling, burning, pain, ataxia, loss 
of deep tendon reflex, and reduced sense of touch, vibration, and proprioception.  Motor 
symptoms may include weakness, balance disturbances, and difficulty performing fine motor 
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skills and a diminished or absent deep tendon reflex.  Motor symptoms are less frequent due to 
the neurotoxic agent’s inability to cross the blood–brain barrier in concentrations significant 
enough to cause harm (Bakitas, 2007; Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007).  
The autonomic system may also be affected, resulting in constipation, urinary retention, sexual 
dysfunction, and altered blood pressure (Bakitas, 2007; Visovsky et al., 2007; Wilkes, 2007).   
Sensory changes in the toes and feet are usually first to be noticed, followed by in the 
fingers and the hands, progressing in a distal–proximal fashion to the ankles and wrist in a 
stocking-glove manner (Park et al., 2013; Wolf et al., 2008).  Chemotherapy-induced peripheral 
neuropathy symptoms are most commonly distributed in a bilateral and symmetrical pattern.  It 
is not uncommon for CIPN symptoms to intensify after the neurotoxic agent has been 
discontinued; this is referred to as coasting and is the result of cumulating concentrations of the 
neurotoxic agent within the body system.  In some instances, CIPN symptoms may occur 
gradually over a prolonged period.  But it is not uncommon for CIPN symptoms to appear 
suddenly and intensely (Wilkes, 2007).    
The impact of CIPN varies and, thus, affects patients differently.  Cumulatively, CIPN 
symptoms may negatively alter a patient’s ability to perform routine activities, functions, and 
behaviors.  Specifically, patients experiencing CIPN symptoms will often report difficulties such 
as with sleeping, driving, standing, walking, climbing stairs, balancing, opening containers, 
holding onto things, cooking, cleaning, flipping pages of paper, wearing certain shoes and 
jewelry, exercising, and socializing (Speck et al., 2011; Tofthagen, 2010).  The most common 
symptoms reported include burning, muscle aches, and sensitivity to cold (Tofthagen, 2010).  
Patients with CIPN reported a variety of symptoms in their feet, including the feelings of “ice 
cold,” “walking on hot coals,” or “sandpaper on the bottom of your feet” (Tofthagen, 2010).    
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The characteristics of CIPN depend upon the specific chemotherapy agent used, as well 
as when the agent is introduced in the treatment protocol and the dosage amount.  Induction 
chemotherapy is the initial administration of the therapy, the goal of which is to achieve 
significant cytoreduction, resulting in complete remission (Airley, 2009). 
Consolidation/intensification chemotherapy is administered once remission has been 
achieved in order to ensure the disease remains in remission, thus increasing overall patient 
survival rates.  Adjuvant chemotherapy is administered once the disease has been eradicated by 
localized treatment, such as surgery or radiation.  Neoadjuvant chemotherapy agents are 
administered prior to local therapy to ensure maximal effect of localized therapy.  For example, 
an agent may be administered to shrink the tumor prior to surgery (Airley, 2009).   
Maintenance chemotherapy is administered in lower doses over a prolonged period.  This 
form of treatment is most often administered in an outpatient or community clinic with the goal 
of prolonged remission (Airley, 2009).  Salvage chemotherapy is an agent given when all other 
treatments have failed, with the purpose of controlling the disease and/or providing palliative 
care.  Lastly, combination chemotherapy is the administration of a combination of agents, thus 
maximizing the effectiveness of the agents to kill the tumor cells throughout various points of the 
cell cycle (Airley, 2009). 
Although chemotherapy agents will vary in the timing of administration, they also vary in 
their chemical composition, resulting in several distinct classes of agents.  The incidence of 
CIPN and subsequent symptoms depend unto the class of the chemotherapy agent used and the 
parts of the nervous system that may be targeted by the various classes of agents (Armstrong et 
al., 2005; Wilkes, 2007).  Platinum compounds consist of cisplatin, carboplatin, and oxaliplatin.  
CIPN has been reported in 57%–92% of cancer patients who received cisplatin (Armstrong et al., 
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2005; Wilkes, 2007).  Cisplatin has been known to cause sensory symptoms that progress to a 
mixture of sensorimotor symptoms and may also affect the autonomic nerves.  The occurrence 
depends on the type of platinum analog, total daily dose, and total regimen dose.  The risk of 
developing CIPN symptoms increases as the cumulative dose reaches 300 mg/m² (Armstrong et 
al., 2005; Wilkes, 2007).  Research has indicated that cisplatin will affect large axon fibers, 
causing axonal swelling, loss of sense of position, and vibration.  Cisplatin has been associated 
with Lhermitte’s sign, which is a lightning-like sensation that begins in the neck and may extend 
posteriorly down the legs during neck flexion.  The cause for these symptoms is postulated to be 
the result of dorsal column irritation within the spinal cord (Armstrong et al., 2005; Wilkes, 
2007).  Motor dysfunction is typically seen after sensory loss (Armstrong et al., 2005; Wilkes, 
2007).  CIPN typically presents late in the treatment or after the treatment has been completed 
(Armstrong et al., 2005; Wilkes, 2007). 
Oxaliplatin has been shown to cause CIPN symptoms in 82% to 92% of cancer patients 
(Armstrong et al., 2005; Wilkes, 2007).  It is believed that oxaliplatin will interfere with ion 
conductance within the axon, thus affecting the neuron’s ability to become “excited” (Armstrong 
et al., 2005; Wilkes, 2007). Oxaliplatin has been associated with two types of neuropathy.  The 
first is similar to that of cisplatin in that the large fibers are primarily targeted, causing distal 
sensory neuropathy.  The second type of neuropathy is acute in that it may occur within 30–60 
min of the infusion.  Cancer patients may develop dysesthesias of the hands and feet, jaw 
tightness, and a sensation of loss of breath (Armstrong et al., 2005; Wilkes, 2007).  Acute 
neuropathy symptoms have been reported to be exacerbated by exposure to the cold, as well as 
the dose and infusion time of a particular agent.  The risk for developing symptoms increases as 
the cumulative dose reaches 750 to 800 mg/m² (Armstrong et al., 2005; Wilkes, 2007). 
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A recent prospective study investigated the incidence and severity of acute oxaliplatin-
induced peripheral neuropathy in 170 patients diagnosed with metastatic colorectal cancer.  The 
patients, who had a mean age of 63.7 years, received either a combination of leucovorin, 5-
fluoruracil, and oxaliplatin, or a combination of capecitabine and oxaliplatin.  The National 
Cancer Institute’s Common Toxicity Criteria were used to assess severity of accumulation 
oxaliplatin sensory and motor neuropathy symptoms.  Sensory and motor nerve conduction 
studies were performed on the ulnar, radial, peroneal, and sural nerves and were repeated after 
six courses (oxaliplatin planned dose, 510 mg/m²) and 12 courses (oxaliplatin planned dose, 
1,020 mg/m²) of the cepecitabine regiments and after four courses (oxaliplatin dose, 520 mg/m²) 
and eight courses (oxaliplatin dose, 1,040 mg/m²; Argyriou et al., 2013). 
Argyriou and colleagues (2013) found that 85.9% of the patients experienced acute 
oxaliplatin-induced peripheral neuropathy and 72.4% of patients experienced chronic oxaliplatin-
induced peripheral neuropathy with the worst symptoms associated with the cumulative dosages 
of oxaliplatin (Spearman rho = 0.171; p = .026).  The incidence of acute oxaliplatin-induced 
peripheral neuropathy was also significantly correlated with the incidence (r = 0.601; p < .001) 
and severity (r = 0.702; p < .001) of chronic oxaliplatin-induced peripheral neuropathy.  
Argyriou and colleagues (2013) also noted that sensory action potentials in all three sensory 
nerves experienced deterioration.  Thus, the results of the study suggest that oxaliplatin may 
induce acute and chronic peripheral neuropathy, which was accompanied by amplitude 
deterioration of sensory action potentials, which was linked to chronic neuropathy (Argyriou et 
al., 2013).  The conclusion reached by Argyriou and colleagues (2013) is consistent with 
previous research, which has shown oxaliplatin to cause sensory peripheral neuropathy 
accompanied by changes in nerve conduction velocities.  
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Taxanes, which are plant-derived poisons, include paclitaxel and docetaxel, and will 
often cause microtubular aggregation (Armstrong et al., 2005; Wilkes, 2007).  Chemotherapy-
induced peripheral neuropathy associated with pacelitaxel and docetaxel depends on the agent 
used, administration schedule, cumulative dose, and whether or not it is combined with another 
agent (Armstrong et al., 2005; Wilkes, 2007).  It has been reported that 59% to 78% of patients 
who receive doses of at least 200 mg/m² and up to a cumulative dose of 1,400 mg/m² of 
paclitaxel may experience neuropathy that is mild to moderate in nature (Armstrong et al., 2005; 
Wilkes, 2007).  Peripheral neuropathy symptoms associated with docetaxel, which occur in 20% 
to 58% of cancer patients, are usually not present until the cumulative dose exceeds 600 mg/m².  
Docetaxel has been known to cause damage to small fibers, resulting in sensorimotor symptoms 
(Armstrong et al., 2005; Wilkes, 2007). 
The incidence of taxane-induced peripheral neuropathy is contingent on various factors, 
such as the treatment schedule, single dose per course, and cumulative dose.  Other factors, such 
as prior or simultaneous administration of platinum compounds or vinca alkaloids, age, 
preexisting peripheral neuropathy due to other medical conditions, such as hereditary ones 
associated with nutritional agents, paraneoplastic, diabetes mellitus, and alcohol abuse.  It is 
suggested that when patients receive a combination of paclitaxel plus cisplatin or paclitaxel plus 
carboplatin, peripheral neuropathy may present as axonal, predominately sensory peripheral 
neuropathy that is mild to severe.  Patients who receive paclitaxel plus cisplatin may experience 
peripheral neuropathy 69.2% of the time, whereas patients who receive paclitaxel plus 
carboplatin may experience peripheral neuropathy 66.6% of the time (Argyriou, Koltzenburg, 
Polychronopoulos, Papapetropoulos, & Kalofonos, 2008).   
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Vinca alkaloids, which consist of vincristine, vindesine, and vinblastine, have been 
associated with peripheral neuropathy.  Vincristine has been associated with the greatest effects 
(Armstrong et al., 2005; Wilkes, 2007).  Vincristine has been shown to cause peripheral 
neuropathy in 57% of cancer patients when the cumulative dose exceeds 6 mg/m².  Vincristine, 
which may cause aggregation of microtubules, thus causing degeneration and atrophy of 
peripheral nerve fibers, may cause the symptoms of pain and temperature sensation (Armstrong 
et al., 2005; Wilkes, 2007). 
The chemotherapy agent bortezomib has been shown to cause CIPN symptoms in 35% of 
patients.  The symptoms are most often sensory in nature and rarely involve motor deficits.  
Thalidomide has been associated with CIPN symptoms in 25% to 81% of patients.  Lastly, 
thalidomide predominantly causes sensory symptoms, with the risk of symptom development 
increasing as the cumulative dose exceeds 400 mg/m² (Armstrong et al., 2005; Wilkes, 2007). 
Although all cancer cells have six common characteristics, there are over 200 different 
types of cancer.  The heterogeneity of cancer is reflected in the various treatment types.  
Chemotherapy is a general term for a variety of classes of drugs that may be administered alone 
or in combination with other treatments, as well as at various times throughout the cancer 
journey.  Despite the numerous types of chemotherapy agents, a common side effect is 
chemotherapy-induced peripheral neuropathy. 
Pathophysiology of Chemotherapy Induced Peripheral Neuropathy  
The symptoms patients experience are due to the neurotoxic effects chemotherapy agents 
have on the peripheral nervous system.  Briefly, the nervous system has two main components: 
the central nervous system (CNS) and the peripheral nervous system (PNS).  The central nervous 
system consists of the brain and spinal cord.  The human system is continuously immersed with 
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sensory information from a variety of sources from the environment, as well as from movement, 
touch, awareness of the body in space, sight, sound, and smell.  During high-order motor 
behaviors, such as walking, the brain and central nervous system (CNS) must correlate the 
various sensory inputs with motor outputs in order to control the body as it moves and interacts 
with the environment (O’Sullivan & Schmitz, 2007).  The CNS will use this information to 
modulate movement by both feedback and feedforward control.  Feedback control occurs during 
movement, in which sensory information is used to monitor and adjust active movement.  
Feedforward control is proactive and utilizes sensory information that has been learned through 
previous experience to send signals prior to the movement to allow anticipatory postural 
adjustments to be made to control posture or movement.  Thus, sensory information plays critical 
roles in movement in that sensory information will aid in the selection of proper motor actions in 
response to the environment and adapt and shape motor programs through feedback, allowing for 
corrective actions to occur in response to a dynamic environment (O’Sullivan & Schmitz, 2007). 
The main task of the PNS is to convey signals of information, such as sense of touch, 
pain, temperature, position, and vibration sense, from the periphery to the CNS.  The 
responsibility for signal transmission belongs to the neuron, which is the basic component of the 
nervous system and is composed of three distinct structures: the cell body, the dendrites, and the 
axon (Magill, 2013).  The neuron generates electrical signals from one part of a cell to another 
part of the same cell or a neighboring cell.  For most neurons, this electrical signal will cause the 
release of neurotransmitters, which are chemical messengers that allow cells to communicate 
with one another (Cuccurullo, 2010).  Each neuron has a cell body (or stoma) within which the 
cell’s nucleus and ribosomes reside.  Branching out from the cell body are dendrites, which are 
responsible for receiving signals from other cells.  The long extension from the cell body is 
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called the axon, and may also be referred to as the nerve fiber (Cuccurullo, 2010).  The axon 
extends from the cell body and carries the output signal to other cells.  The axon can vary in 
length, ranging from a few microns to over a meter (Cuccurullo, 2010).   
Neurons are classified according to their function.  A neuron may either receive or send 
information by a neural impulse.  A signal may be sent to, from, or within the central nervous 
system, which is composed of the brain and spinal cord.  Neurons have three functional classes, 
which include sensory neurons (also called afferent neurons), motor neurons (also called efferent 
neurons), and interneurons, which originate and terminate in the brain or spinal cord, acting as 
connections between axons descending within the brain or spinal cord (Magill & Anderson, 
2013).  Sensory neurons send neural impulses to the central nervous system (CNS), whereas 
motor neurons send neural impulses from the CNS to skeletal muscle fibers (Magill & Anderson, 
2013).   
The PNS is composed of afferent and efferent divisions.  The afferent neurons will 
transmit information from sensors located in the periphery to the CNS, whereas the efferent 
neurons will transmit signals from the CNS to muscles or glands (Widmaier, Raff, & Strang, 
2006).  The peripheral nervous system has three functional divisions, which are the sensory 
nerves, motor nerves, and the autonomic nerves.  The sensory nerves sense touch, pain, 
temperature, position, and vibration sense.  The motor nerves are responsible for voluntary 
movement, muscle tone, and coordination.  The autonomic nerves are responsible for the control 
of intestinal motility, blood pressure, and involuntary muscles (Widmaier et al., 2006).   
Anatomically, the afferent nerves of the peripheral nervous system are composed of small 
and large fibers.  The small fibers are unmyelinated and consist of nerves that sense pain and 
temperature.  The large nerve fibers are myelinated and consist of nerves that sense position and 
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vibration, as well as motor control (Armstrong et al., 2005).  The small nerve fibers are primarily 
composed of microtubules, which transport proteins throughout the nerve fiber.  Large nerve 
fibers are primarily composed of neurofilaments, which comprise the axon’s framework. Sensory 
nerves terminate at the level of the skin and extend to the dorsal root ganglion, connecting with 
either the dorsal column via a large fiber or the spinothalamic tract via a small fiber in the spinal 
cord (Armstrong et al., 2005). 
The somatosensory system, which consists of muscle spindles, Golgi tendon organs, joint 
receptors, and cutaneous receptors, contributes to the modulation of spinal pattern generators, 
modulation of motor commands, and perception and control of movement through sensory 
information.  Specifically, there are several different types of receptors at the end of the afferent 
nerves, which provide information with regard to length and tension in muscles and tendons, 
sense of joint positions, as well as heat, cold, touch, pressure, and skin of body parts affected by 
the action of muscles.   
Collectively, these distinct receptors and their afferent nerves, which may be referred to 
as the somatosensory system, provide the CNS information with respect to muscle length and 
tension, movement of the joints, the effect of movement on the overlying skin, as well how the 
body is interacting with the external environment. The CNS will interpret this information and 
send a command via efferent nerves to implement an action (Widmaier et al., 2006).  These 
sensory neurons will provide information about mechanical stimuli, temperature changes, 
potential damage to the skin, body and limb movement and position, as well as velocity and 
muscle activation (Magill & Anderson, 2013; Shumway-Cook & Woollacott, 2012).  Of 
particular interest may be cutaneous receptors, which consist of mechanoreceptors, 
thermoreceptors, and nociceptors, which are located within sensitive areas of the skin, with as 
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many as 25,000 per square centimeter (Shumway-Cook & Woollacott, 2012).  Cutaneous 
sensory receptors provide information about the body’s orientation within the immediate 
environment and provide information necessary for reflexive responses.  Cumulatively, sensory 
receptors within the somatosensory system provide information by afferent nerve fibers to the 
spinal cord, which allows for the modulation of locomotion.   
The neurotoxic effects of chemotherapy agents on the peripheral nervous system are 
wide-ranging, targeting many components of the peripheral nervous system, such as the axons 
and cell bodies of dorsal root ganglion neurons, and resulting in axonal damage, which is 
characterized by a decrease in intraepidermal nerve fiber density and terminal arbor degeneration 
(Han & Smith, 2013).  Chemotherapy agents will also exert their toxicity on mitochondria, 
causing them to become swollen and vacuoled, as well as create oxidative stress, causing 
inflammation.  Pathologically, the dorsal root ganglion neurons and surrounding satellite cells 
may negatively alter the expression of various ion channels, neurotransmitters, and receptors, as 
well as exhibit altered gene expression.  The mitochondrial dysfunction and IENF loss seem to 
be directly correlated to the presence of pain.  Cumulatively, these changes cause various sensory 
symptoms, such numbness, tingling, burning, pain, and reduced sense of touch, as well as motor 
symptoms, such as may include weakness, balance disturbances, and difficulty performing fine 
motor skills, which are frequently reported by cancer patients undergoing chemotherapy 
treatment (Bakitas, 2007; Han & Smith, 2013; Murillo et al., 2008; Park et al, 2013; Visovsky et 
al., 2007; Wilkes, 2007). 
Although there is a wide range of neuronal targets for various chemotherapy agents, it is 
estimated that platinum drugs (antineoplastic agents), such as cisplatin and oxaliplatin, may 
generally target the DRG and ion channels.  Oxaliplatin may cause an acute peripheral 
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neuropathy by causing the nodal axonal voltage-gated sodium and calcium channels to become 
dysfunctional (Argyriou, Bruna, Marmiroli, & Cavaletti, 2012).  In animal models, rats treated 
with oxaliplatin did not experience degeneration of peripheral nerve axons (A-fibers and C-
fibers), but there was a partial loss of intraepidermal nerve fibers, which was accompanied by a 
reduction in sensory nerve conduction velocity that lasted well after the cessation of treatment, 
suggesting deficits may be chronic rather than acute.  There was no reduction in motor nerve 
conduction velocity.  The rats treated with oxaliplatin also experienced slower and more irregular 
and spontaneous discharges patterns in A-fibers and C-fibers, swollen and vacuolated 
mitochondria, and mechano-allodynia, mehcano-hyperalgesia, and cold-allodynia, which is 
consistent with patient-reported symptoms (Xiao, Zheng, & Bennett, 2012).  It has also been 
proposed that platinum compounds will alter the tertiary structure of DNA by forming 
intrastrand adducts and interstrand crosslinks, thus inducing apoptosis and causing neuronal 
apoptosis through oxidative stress and mitochondrial dysfunction (Argyriou et al., 2012).  
Taxanes, such as paclitaxel and docetaxel, are thought to disturb the function of the 
microtubules of the mitotic spindle, thus negatively affecting axonal transport, which may evoke 
the typical “dying-back” pattern.  Taxanes will also evoke certain cellular processes, such as 
macrophage activation in both the DRG and peripheral nerve, as well as microglial activation 
within the spinal cord, which has been postulated to contribute to the development of taxane-
induced peripheral neuropathy. Recent studies suggest that paclitaxel may cause the axonal 
microtubules to undergo a massive polar reconfiguration, which is often accompanied by 
impaired organelle transport, resulting in degeneration of intraepidermal terminal arbors of 
primary afferent neurons, and is associated with increased incidence of swollen and vacuolated 
axonal mitochondria in A-fibers and C-fibers (Argyriou et al., 2012).  Furthermore, paclitaxel 
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and docetaxel can induce a ganglionopathy that attacks the cell bodies, particularly those of the 
dorsal root ganglia (DRG), or myelinopathy with primary segmental demyelination.  Taxanes 
have been known to affect sensory neurons, especially myelinated nerve fibers of vibration 
sensation and proprioception.  Nerve biopsies have shown that taxane-induced peripheral 
neuropath are mostly ganglionopathic in nature, rather than axonopathic (Argyriou et al., 2008).   
Taxane-induced peripheral neuropathy may most often present a sensory neuropathy, 
although motor neuropathy is not uncommon.  The primary affected fibers are the thick 
myelinated nerve fibers conducting sensation and sense of position.  Symptoms may also include 
loss of pain and temperature sensation and loss of tendon reflexes (Argyriou et al., 2008).  
Electrophysiological abnormalities include decrease or loss of sensory response, slower motor 
conduction velocities, or F-wave latency delay, suggesting primary demyelination, as well as the 
possibility that damage has also occurred to the myelin-Schwann cells.  Secondary 
demyelination may also occur, which consists of minor increases in distal latency and decreased 
conduction velocity (Argyriou et al., 2008).  It has also been noted that sural nerves may 
experience reduced or loss sensory nerve potentials velocity (Argyriou et al., 2008).   
While taxanes may produce a symmetric, axonal neuropathy that is predominately 
sensory in nature, motor neuropathy may occur but is often difficult to recognize because of the 
very mild weakness that occurs in muscles.  However, when motor neuropathy does occur, 
reduction occurs in the compound muscles action potential response that can be noted, which 
indicates axonal loss, highlighted by electromyography (EMG), showing active denervation 
changes in the distal muscles of the lower limb velocity (Argyriou et al., 2008).   
Two to 3 days after paclitaxel treatment, myopathy with proximal weakness and 
myopathic EMG changes are known to occur.  High doses of taxanes have been known to cause 
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severe myalgia, particularly in the shoulder and paraspinal muscles.  Biopsies of nerves 
subjected to taxanes have shown nerves to experience axonal degeneration and have reduced 
myelinated nerve fiber density and loss of large-fiber velocity (Argyriou et al., 2008).  However, 
recent research using in vivo chronic animal models of CIPN in female Wistar rats what were 
administered cisplatin, paclitaxel, or a combination of both, found that while there was a 
decrease in nerve conduction velocity, there was no change in myelin structure (Gilardini, 2012).  
Thus, the exact pathophysiology of CIPN remains unknown at this time.   
The risk for developing CIPN can be further increased in individuals who have been 
previously been diagnosed with diabetes, alcohol-related peripheral neuropathy, ischemic 
disease, vitamin deficiencies, renal insufficiency, prior exposure, or concurrent use of neurotoxic 
agents (Armstrong et al., 2005; Wilkes, 2007).  Additionally, the incidence and severity of CIPN 
depends upon the intensity and duration of a single dose, as well as the total number of doses and 
any prior or concurrent doses.  Furthermore, any prior or concurrent exposure to cisplatin may 
increase the incidence and severity of CIPN.  A medical history of diabetes and alcohol abuse 
can also affect the incidence and severity of CIPN (Jaggi & Singh, 2012).  Although CIPN may 
reverse itself once the agent has been stopped, many times CIPN symptoms may be irreversible 
(Wilkes, 2007). 
Due to the neurotoxic effect of chemotherapy agents, the CNS may not receive vital 
information.  As such researchers have begun investigating the effects of chemotherapy agents 
on the somatosensory system.  Visovsky and Daly (2004) evaluated the change in CIPN 
symptoms within cancer survivors undergoing chemotherapy.  To evaluate the presentation of 
CIPN and changes in nerve function, Visovsky and Daly evaluated the vision, hearing, deep 
tendon reflexes, vibratory sense, cutaneous sensation, gait, balance, muscle strength, and 
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orthostatic blood pressure of cancer survivors undergoing chemotherapy.  Measures were 
assessed at baseline, which was before the participants started receiving chemotherapy.  The 
participants were reassessed at 4 weeks and 12 weeks into treatment.  Gait and balance were 
assessed using portions of the Tinetti Performance-Oriented Assessment of Balance and Gait 
instrument, which requires the participant to display mobility and balance throughout a series of 
maneuvers.  The investigators observed gain initiation, step height, step length, step symmetry, 
step continuity, path deviation, trunk stability, walk stance, and turning while walking.  The test 
is a valid and reliable measure that focuses on maintenance of position, postural responses to 
voluntary movement, and perturbation and gait mobility.  The test is simple to administer; 
however, the scoring criteria are vague.  Thus, it is difficult to detect small changes in 
spatiotemporal gait parameters (O’Sullivan & Schmitz, 2007).  Visovsky and Daly (2004) also 
assessed deep tendon reflexes using Babinski’s reflex hammer, vibratory sense using a tuning 
fork, cutaneous sensation using Semmes-Weinstein monofilaments, and muscle strength using a 
handheld dynamometer (Visovsky & Daly, 2004). 
Visovsky and Daly (2004) observed changes in vision, hearing, deep tendon reflexes, 
vibratory sense, cutaneous sensation, balance, muscle strength, and orthostatic pressure; gait 
remained unchanged.  Although the changes in outcomes may not have been statistically 
significant, Visovsky and Daly noted that this may be due to the small, homogenous sample size.  
Furthermore, an interesting finding in the present study was that the participants experienced an 
18% decline in dynamic balance but no changes in gait.  This discrepancy may by a function of 
the tool, as the Tinetti Performance-Oriented Assessment of Balance and Gait instrument uses a 
vague scoring criterion and thus cannot detect small changes in spatiotemporal gait parameters.  
However, the Tinetti Performance-Oriented Assessment of Balance and Gait may not have been 
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the best tool to use, as a recent study suggested that to assess risk of falls for those with 
neuropathy, either the Functional Reach test, Timed Up and Go test, the Berg Balance Scale, or 
the Dynamic Gait Index may be more appropriate (Jernigan, Pohl, Mahnken, & Kluding, 2012).  
More specifically, Jernigan and colleagues (2012) suggested that in the clinical setting sensitivity 
is the most important measure because high sensitivity corresponds to more true positives and 
fewer false negatives.  Thus, the Timed Up and Go test may be a better test to asses fall risk due 
to its high sensitivity of 90% and high diagnostic accuracy at 88.9%.  Furthermore, Visovsky and 
Daly stated the data may have been more accurately and consistently captured had a highly 
trained examiner performed the data collection.  The examiners in this study are experienced 
nurse practitioners; thus, their lack of expertise on the clinical measures may have resulted in 
inherent intrasubject variability.  However, the results of the current study suggested a trending 
decline in peripheral nerve function through treatment and the current clinical outcomes used, 
thus warranting further investigation.   
Lastly, an interesting finding in the present study was that participants experienced an 
18% decline in dynamic balance, as well as a reporting of recurrent falls, which are significant 
events, especially in the older population, as falls have been linked to serious injuries and 
disabilities, loss of independence, fear of falling, and increased mortality rates (Kelsey, Procter-
Gray, Hannan, & Wenjun, 2012; Visovsky & Daly, 2004). 
Hilkens, Verweij, Vecht, Stoter, and van den Bent (1997) conducted a series of case 
reports of cancer survivors undergoing chemotherapy treatment with docetaxel, a taxane-based 
agent.  Common symptoms experienced throughout the case reports were sensory signs and 
symptoms that started with paresthesia and numbness in the hands and feet.  The case reports 
insinuated a loss of tendon reflexes and vibratory perception, along with disabling pain, which 
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suggested involvement of small, unmyelinated nerve fibers.  In conjunction with patient-reported 
numbness and paresthesia, several of the patients reported a loss of dexterity and an increasingly 
unsteady gait (Hilkens et al., 1997). 
Hile, Fitzgerald, and Studenski (2010) conducted a case study to investigate the severity 
and impact of neurotoxic chemotherapy on one individual.  The individual being studied was 
diagnosed with breast cancer and received paclitaxel after undergoing a curative mastectomy.  
Before the patient began taxane chemotherapy, baseline testing was administered, which 
consisted of the Short Physical Performance Battery and quantified standing, walking, and 
repeated chair stands.  The patient’s baseline testing indicated an active woman with no 
functional deficits of neuropathic symptoms.  However, after three cycles of paclitaxel therapy 
over the course of 12 weeks, the patient experienced a 50% decline in her performance-based 
measures.  The patient now required a cane for walking as her gait became unsteady and 
decreased by 0.46 m/s.  Additionally, at 12 weeks, the patient scored 1/4 for balance (3.6 s 
semitandem), 3/4 for gait (0.74 s), and 1/4 for chair stands (16.9 s), as well as reported 
difficulties in performing mobility-related tasks and a higher incidence of falls.  Furthermore, 
testing revealed a significant decrease in balance (Hile et al., 2010).  The results of this case 
study suggested that chemotherapy may have a deleterious impact on physical function.  Even 
more important is the reporting of recurrent falls, which are significant events, especially in the 
older population, as falls have been linked to serious injuries and disabilities, loss of 
independence, fear of falling, and increased mortality rates (Kelsey et al., 2012).  Therefore, 
research suggested that certain chemotherapy agents may negatively affect proprioception and 
sensory feedback, thus impairing certain aspects of function and mobility. 
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In summary, chemotherapy-induced peripheral neuropathy is characterized by multiple 
sensory changes, which include mechanical allodynia, cold allodynia, slowing of sensor nerve 
conduction velocity, and loss of heat sensitivity.  Although the exact pathophysiology of CIPN 
remains unclear, research suggested decreases in intraepidermal nerve fiber density and terminal 
arbor degeneration, which are associated with mitochondrial dysfunction, mitotoxicity, and 
oxidative stress (Han & Smith, 2013).  Cumulatively, CIPN causes a host of uncomfortable and 
painful sensations throughout the periphery of a cancer patient’s extremities.  
In addition to the unconformable and often painful sensory nature of chemotherapy-
induced peripheral neuropathy, CIPN may also cause a loss of peripheral sensation, 
proprioception, and lower-extremity muscle weakness, which may interfere with balance and 
gait (Tofthagen et al., 2012).   
Motor activity, such as gait, is the result of the integration of neuronal signal of the motor 
control systems within the central and peripheral nervous system (Shumway-Cook & Woollacott, 
2012).  Motor control may be defined as the “ability to regulate or direct the mechanisms 
essential to movement” (Shumway-Cook & Woollacott, 2012, p. 3).  Movement is the result of 
three factors and their interactions with one another.  These three factors are the individual, the 
task, and the environment (Shumway-Cook & Woollacott, 2012).    
Although there may be just three factors that interact to produce movement, the way in 
which these three factors interact is complex, resulting in multiple theories of motor control and 
how movement is controlled.  The first of the two leading theories is related to motor programs, 
or the central pattern generator (CPG), which is a neural circuit of networks that generate 
rhythmic motor patterns without the influence of sensory or descending inputs (Kelso, 1995).  A 
central pattern generator (CPG) is a genetically defined (inherited) central organization located 
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within the brain stem or spinal cord.  It is theorized that there are specific patters of motions, 
such as for walking and swimming, and that these patterns may be multifunctional, producing 
several variations within a movement.  For example, during gait, one may walk, run, skip, hop, 
bound, or jump (Kelso, 1995). 
According to the motor program theory, a set of commands defines and shapes an action, 
which is then modified by sensory information.  A stimulus (a command neuron) will trigger and 
initiate the CPG’s action in the brain.  The CPG will then send rhythmic, oscillating instructions 
to the musculature.  These signals (instructions) create limb movement that are often 
characterized as reciprocal and repetitive in nature (MacKay-Lyons, 2002).   
Although research indicates that CPGs are primary contributors to motor control, sensory 
and reflexive processes are needed in order to modify these commands to allow for adaptations 
to the changing environment; thus, central pattern generators are not the sole determinants of a 
movement (Shumway-Cook & Woollacott, 2012).  Premovement information, such as posture 
and body orientation, are used by individuals to prepare for movement, as well as various reflex 
mechanisms, which will aid in the generation of rapid connections in order to successfully 
perform an action in dynamic environments (Schmidt & Wrisberg, 2008).  In this theory, the 
brain stem controls both the CPG and the reflexes that mediate the afferent inputs to the spinal 
cord.  The spinal reflex pathways and descending pathways merge information within a common 
spinal interneuron to integrate various information (Dietz, 2002).  The supraspinal descending 
tracts provide inputs that help shape the output patterns of CPGs.  The mesencephalic locomotor 
region (brain stem) transmits information to the flexors and extensor neurons during flexion and 
extension muscle activations throughout the gait cycle.  The descending tracts also aid in the 
stabilization of gait rhythms (MacKay-Lyons, 2002).   
EFFECTS OF CIPN ON GAIT AND FALL RISK                                                                    43  
The second of the two leading theories is systems theory, which states that in order to 
understand the neural control of movement, one must understand the system’s characteristics in 
which the movement occurs, as well as the external and internal forces that are acting on the 
body (Bernstein, 1967).  Bernstein (1967) studied the body as a whole mechanical system that 
has mass and is subject to external forces, such as gravity, and internal forces, such as inertial 
and movement-dependent forces.  Bernstein suggested that even though two central commands 
may be equal, the two resulting movements may be quite different due to the interplay between 
external forces and variations within initial conditions.  Bernstein also suggested that many 
interacting systems play a role in movement integration (Bernstein, 1967).  Bernstein put forth 
the idea that the body, as a mechanical system, has multiple degrees of freedom that must be 
controlled during movement.  For example, the body contains numerous joints that can flex, 
extend, and sometimes rotate, which will complicate movement.  Bernstein hypothesized that 
control of the various degrees of freedom is hierarchical in nature in that the higher portions of 
the nervous system will control the lower portions of the nervous system, which in turn will 
activate synergies, or groups of muscles, that act as a unit (Shumway-Cook & Woollacott, 2012).    
Over the years, Bernstein’s system theory has evolved into the dynamical systems theory, 
which states that when the individual parts of a system are combined, the individual elements 
will start to behave collectively, resulting in an ordered way (Shumway-Cook & Woollacott, 
2012).  When applied to motor control, dynamical systems theory may predict movement based 
on the elements involved and their interactions, ignoring any specific commands or motor 
programs of the nervous system (Shumway-Cook & Woollacott, 2012).  Dynamical systems 
theory states that a new behavior pattern will occur when there is a change in the system, called 
the “control parameter.”  A control parameter is a variable that alters a system’s behavior.  For 
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example, as an animal’s walking velocity increases, it will reach a certain velocity that dictates 
the animal’s behavioral change from a walk to a trot (Shumway-Cook & Woollacott, 2012).  
This is in stark contrast to the theory of central pattern generators, as the dynamical system 
deemphasizes the existence of central nervous system commands (Shumway-Cook & 
Woollacott, 2012). 
A key concept in dynamical systems theory is that of variability and its role in movement 
control (Shumway-Cook & Woollacott, 2012).  Dynamical systems theory states that human 
movement functions optimally due to its inherent variability, which may consist of the variations 
that normally occur during motor performance throughout multiple task repetitions.  In the 
central pattern generator theory, variability is the result of errors that occur during motor 
performance and assumes that these errors can be reduced through skill acquisition, which results 
in decreases in variability and error (Shumway-Cook & Woollacott, 2012).  On the other hand, 
dynamical systems theory views variability as positive, as it allows for flexible and adaptive 
strategies to occur as the environment changes, which is essential for normal movement to occur.  
In this theory, a lack of variability may result in injury, whereas excessive variability results in 
movement impairments, such as with persons with ataxia (Shumway-Cook & Woollacott, 2012).  
Thus, dynamical systems theory views a small amount of variability as positive because it 
indicates highly stable and preferred movement patterns, which is called an attractor state.  An 
example of an attractor state with walking is a person walking at various speeds who, barring 
outside influences, will walk at a preferred state that is the most energetically efficient 
(Shumway-Cook & Woollacott, 2012). 
The dynamical systems theory does have its limitations.  Although this theory does take 
into consideration all of the contributors to movement, such as muscles and skeletal systems, as 
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well as gravity and inertia, it does minimize the role of the nervous system.  The dynamical 
system states that the nervous system in isolation does not predict movement, which is contrary 
to central pattern generator theory (Shumway-Cook & Woollacott, 2012). 
Despite these differences, both theories of motor control must incorporate the basic 
systems of control: open-loop and closed-loop control systems.  The primary difference between 
these two systems is that a closed-loop system involves feedback, whereas an open-loop system 
does not.  In human movement, such as walking, the feedback is afferent information sent by 
various sensory receptors to the control center, which will provide modulation of movement 
while it is in progress (Magill & Anderson, 2013).  
Regardless of the theory, movement depends on the coordinated integration of the 
individual, the task, and the environment.  From the CPG perspective, movement is the result of 
a central command that sends signals via inherent neural networks.  From the dynamical system 
theory (DST) perspective, movement is based on the elements involved and their interactions, 
ignoring any specific commands.  Furthermore, although the origin of movement may be very 
different between these two theories, both CPG and DST rely on peripheral sensory information 
and joint receptor and muscle spindle information sent via afferent pathways for the modulation 
of locomotion.  Previous research using animal subjects has shown that when sensory nerves are 
cut (deafferented), commands can still be processed and locomotion is generated.  However, the 
resulting locomotion is unmodulated and often sloppy and uncoordinated.  Research has shown 
that, even though CPGs allow for locomotion to occur in the absence of proprioception, afferent 
feedback is a prime contributor in the generation of stable and modulated movement (MacKay-
Lyons, 2002).  Specifically, afferent feedback provides position sense, direction, and force 
movement, resulting in rhythmic movements (MacKay-Lyons, 2002).   
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Whereas a central pattern general (CPG) may provide a movement command, load 
receptors in the muscles and tendons provide important information that allows for a smooth gait 
pattern.  For instance, load receptors located in the tibias anterior provide information to the CNS 
that aids in the regulation of the activation time and duration for the gastrocnemius.  Receptors in 
the hip provide afferent formation that is critical during phase transitions for different movement 
patterns (Dietz, 2002). 
Thus, sensory information plays a critical role in movement in that sensory information 
will aid in the selection of proper motor actions in response to the environment and adapt and 
shape motor programs through feedback, allowing for corrective actions to occur in response to a 
dynamic environment (O’Sullivan & Schmitz, 2007).  Sensory feedback control plays a critical 
role in adjusting stride-to-stride limb trajectories in order to smooth out irregularities during 
unperturbed movements and safely navigate and maintain balance (Gandevia & Burke, 1992).  
Sensory information and information provided by Golgi tendon organs and muscle spindles 
provide critical information for the generation of rhythmic alternating contractions in muscles, 
indicating that sensory information plays a role in locomotion.  Specifically, sensory information 
contributes to stepping frequency.  Furthermore, joint receptors and the muscle spindle afferent 
(from stretch hip flexors) contribute to the regulation of phase transitions and timing of when the 
legs should swing forward, thus contributing to the rhythm of gait (Dietz & Duysens, 2000; 
Shumway-Cook & Woollacott, 2012). 
Sensory information and proprioceptive information are also critical for the regulation 
and control of one’s body position through locomotion.  The ability to maintain postural stability 
during locomotion is a key and fundamental task.  Postural control, which may be defined as the 
ability to control one’s body position in space, and maintaining an appropriate relationship 
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between one’s body segments and between the body and the environment for a task are critical in 
order to keep the body stable and oriented.  Postural stability, also known as balance, is the 
ability to control the center of mass in relationship to the base of support.  The center of mass is 
defined as a point that is at the center of the total body mass (Shumway-Cook & Woollacott, 
2012).  The base of support is defined as the area of the body that is in contact with the support 
surface.  Previous research indicates that the central nervous system will control the body’s 
center of mass in order to maintain postural control.  Another term and concept critical to 
postural control is center of pressure.  The body will generate forces in order to control the 
motion of the center of mass.  The center of pressure is the center of the distribution of the total 
forces applied to the supporting surfaces.  The center of pressure moves continuously around the 
center of mass to keep it within the base of support (Shumway-Cook & Woollacott, 2012).   
Every task requires an orientation component and stability component, and these 
requirements will change depending upon the task and the environment.  During locomotion, 
postural control ensuring orientation and stability is essential.  During gait, the body’s center of 
mass (center of gravity) does not stay within the base of support of the feet; thus, the body is in a 
constant state of imbalance.  However, individuals do not always fall while walking because 
normally the foot that swings forward during gait is placed ahead of and lateral to the center of 
gravity as it moves forward, keeping the center of mass relative to the moving base of support 
(Shumway-Cook & Woollacott, 2012).   
Therefore, there are several neural components that are critical for postural control, such 
as motor processes, which are the organization of muscles to perform actions such as swinging 
the leg forward; sensory/perceptual processes, which consist of organizing and integrating 
various visual, vestibular, and somatosensory systems; and lastly high-level cognitive processes 
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for interpreting the information provided by the sensory and perceptual process in order to 
produce an appropriate action.  According to dynamical systems theory, postural control is due to 
the complex interactions of various body systems working cooperatively to control the body’s 
orientation and stability (Shumway-Cook & Woollacott, 2012).   
Thus, the generation, maintenance, and regulation of gait requires input from specific 
neuronal mechanisms, such as afferent feedback and proprioceptive information and neuronal 
circuits in the spinal cord, thus shaping a movement pattern.  There are three reflex systems that 
contribute to the modulation of gait: the monosynaptic reflex, which is mediated by Ia afferent 
nerves; the cutaneous reflexes, which is mediated by the skin afferents; and the polysynaptic 
reflexes, which integrate afferent inputs from a variety of sources (Dietz, 2002).  
The monosynaptic reflex, also known as the spinal stretch reflexes or myotatic reflex, is a 
preprogrammed response by the body due to a stretch stimulus in the muscle.  When a muscle 
spindle is stretched, the spinal cord receives a signal immediately and responds by having that 
muscle contract.  The myotatic reflex is critical for posture and gait because if the body begins to 
deviate due to an obstacle or change in terrain, the stretch reflex will quickly counter interruption 
and ensure the body’s center of mass is over the base of support.  Furthermore, during gait, this 
reflex, such as the H-reflex of the soleus, may provide compensation for irregularities in the 
ground.  However, it still remains unclear as to the magnitude of the functional impact the stretch 
reflex has during gait.  The monsynaptic reflex system is very sensitive to small inputs, thus only 
responding to small irregularities on the ground.  So, the afferent input that is selected in 
response to what is occurring in the body’s external environment is critical because the neuronal 
signals of the muscle stretch or length is not enough to control the body during gait.  Body 
control requires a combination of afferent inputs (Dietz, 2002). 
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The second reflex system is the cutaneous system.  Muscles will respond to sensory 
nerves that are induced by electrical stimuli.  Various limb muscles will have this response 
mechanism that has a latency similar to that of spinal pathways.  Cutaneous leg muscle reflexes 
are motor task specific, providing profound modulation that depends on the context in which 
they are evoked.  Cutaneous leg reflexes are also nerve specific, which appears to be important 
for function, and may include central pattern generators (Dietz, 2002).   
Lastly, polysynaptic reflexes are mediated by muscle proprioceptive input from group 2 
afferent fibers, which are static muscle spindles or skin.  From a functional perspective, 
polysynaptic reflexes may be particularly important for function because they may provide 
compensatory responses during gait that are more complex than simple stretch–reflex responses.  
The polysynaptic pathway integrates inputs from muscle, joint, and cutaneous afferents, and 
combines these inputs with commands from supraspinal centers to common spinal interneurons.  
The polysynaptic reflex has both excitatory and inhibitory connections for both extensors and 
flexors.  The polysynaptic reflex sensory input determines direction, velocity, and amplitude of 
the bodily adjustments through specific patterns of leg muscle activation needed by individuals 
to maintain their center of gravity over their feet (Dietz, 2002).   
Afferent information for locomotion will be provided from a variety of sources.  In 
addition to receptions in the skin and muscles, afferent information will be provided from visual 
and vestibular sources.  Spinal reflex pathways and descending pathways will converge on a 
common interneuron in which these inputs will be integrated.  For examples, activity from the 
length sensors in muscles (i.e., the muscle spindles) will be reduced by visual feedforward 
information.  Additionally, proprioceptor information from the leg muscles during gait may 
determine the amount and degree of influence of vestibulospinal input to stabilize the body 
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during movement.  On the other hand, the amount and degree of vestibulospinal input will be 
increased when there is a loss or decrease in somatosensory information (Dietz, 2002).   
In summary, gait is a complex behavior.  A stable gait is characterized by postural 
control, which may be accomplished through the production of coordinated rhythmic patterns of 
muscle activation in the lower extremities and trunk and which moves the body forward in the 
desired direction, maintaining the body’s center of mass and center of pressure within the 
established base of support, producing the needed posture dynamic stability throughout 
locomotion. 
As a result, during a stable gait pattern, the body can respond to environmental 
challenges, such as avoiding obstacles; negotiate uneven terrain; and change speed and direction 
as required (Shumway-Cook & Woollacott, 2012).  A disruption in the somatosensory system 
may result in decreased gait modulation and adaptation, interfering with and disturbing a normal 
gait cycle.  A gait cycle is a series of cyclical movements, beginning when the foot contacts the 
ground, which is most often the heel.  This is denoted as the 0% point and is beginning of the 
gait cycle, which is also known as heel contact or heel strike.  The gait cycle is 100% complete 
when the same foot again makes contact with the ground (Neumann, 2002). A stride, which also 
is another term for gait cycle, is the events and their sequences that take place between 
successive heel contacts of the same foot.  A step, on the other hand, is the sequence of events 
that occurs within successive heel contacts of opposite feet.  Therefore, a gait cycle has two 
steps: a right step and a left step (Neumann, 2002).  
A gait cycle may be simply described by its most basic spatial descriptors, which include 
the length of a stride and the length of a step.  Stride length may be defined as the distance 
between two successive heel contacts of the same foot, whereas step length may be defined as 
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the distance between successive heel contacts of the two different feet.  A normal stride length is 
approximately 72 cm (Neumann, 2002).  Step width is also an important spatial descriptor of gait 
and may be defined as the lateral distance between the heel centers of two consecutive foot 
contacts.  Step width is normally between 7 and 9 cm (Neumann, 2002).  Furthermore, foot angle 
may be defined as the angle between the line of progression of the body and the long axis of the 
foot.  A normal foot angle is 7 degrees (Neumann, 2002). 
The gait cycle may be further divided into two major phases: stance and swing 
(Neumann, 2002).  The stance phase begins at right heel contact and continues as long as the 
right foot remains on the ground.  The stance phase ends when the right toe comes off the 
ground.  The swing phase begins when the right toe lifts off the ground and ends when the right 
heel makes contact with the ground once again.  Normally, individuals will spend 60% of their 
time in stance phase and 40% of their gait cycle in swing phase (Neumann, 2002).    
The basic temporal gait descriptors consist of cadence, stride time, and step time 
(Neumann, 2002).  Cadence may be defined as the number of steps per minute; this may also be 
referred to as step rate.  Additionally, stride time is defined as the time for a full gait cycle, and 
step time is defined as the time for completion of a right or a left step (Neumann, 2002).  
Walking speed, which is a combination of spatial and temporal measures, informs the distance 
covered in a given amount of time and may be the best functional measure of an individual’s 
ability to walk.  Normal gait speed is 1.37 m/s (Neumann, 2002). 
The adaptation of gait to environmental demands depends in part upon the somatosensory 
system, which consists of various sensory and proprioceptors that provide the input to modulate 
the gait pattern.  The proprioceptors convey information about the body and the environment to 
the spinal cord via afferent nerves (Dietz, 2002).  However, these are the same nerves in which 
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chemotherapy agents exert their toxic affect.  Tofthagen and colleagues (2012) found that as the 
chemotherapy dosages increased, the presences of neuropathic symptoms increased and muscle 
strength and balance decreased, causing greater difficulty in performing the tasks of walking and 
driving.   
Although gait is a subconscious and highly reproducible movement performed daily, 
previous research suggests that when certain gait characteristics deviate from the normal, an 
individual may be at higher risk for falls.  Research indicates that the majority of falls 
experienced by the elderly will occur during walking.  As with individuals with CIPN, aging will 
result in desensitization of motor units, as well as decreased perceptions of high-frequency 
vibrations, touch, proprioception, and pressure stimuli, indicating a disturbed somatosensory 
system (Prince, Corriveau, Hebert, & Winter, 2007).  Further investigation has shown that 
elderly individuals who fall will display slower gait speeds, decreases in step length, and 
increases in double support times (Shumway-Cook & Woollacott, 2012).  Additionally, elderly 
adults who fall will exhibit increased variability within swing time and stride length, which has 
been shown to predict fall risk (Verghese et al., 2009).  Increased variability within 
spatiotemporal gait parameters has been associated with increased fall risk (Maki, 1997) 
Falling is a significant event, especially for older adults, as falls have been linked to 
serious injuries and disabilities, loss of independence, and increased mortality.  Twenty-three 
percent of falls in adults aged 65–69 resulted in death, with the rate climbing as high as 50% of 
falls resulting in death for adults aged 85 or older.  It is estimated that of the 1.6 million new 
cancer diagnoses in 2013, 77% were individuals over the age of 55 (Alamgir et al., 2012).  
Previous studies have indicates that 20% of patients with CIPN may fall, which is a higher 
percentage than age-matched controls (Mohile et al., 2009, 2011; Tofthagen et al., 2012).  Stone 
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and colleagues (2012) conducted a 6-month prospective study of cancer patients and found that 
50.3% of the patients fell during the follow-up period.  More significantly, more than one-third 
of the falls resulted in soft tissue injuries and 3.2% resulted in fractures.  Bylow et al. (2008) 
reported that 34% of prostate cancer patients undergoing androgen deprivation therapy fell over 
the course of 6 months.  Bylow et al. also noted that these patients experienced significant 
deficits in physical performance as measured by reduced gait speed, balance, and lower body 
strength.  In a very recent study, Gewandter and colleagues (2013) investigated the correlations 
between chemotherapy-induced peripheral neuropathy, functional impairments, and prevalence 
and falls.  Of the 471 participants with CIPN, 12% reported having fallen in the 3 months prior to 
the study and 27% of the participants had impairment in functional capacity.  The participants 
who reported a fall also had higher (worse) sensory and motor neuropathy scores.  Those who 
fell reported struggling to hold a pen, which resulted in difficulty writing, as well as trouble with 
walking (Gewandter et al., 2013). 
A study conducted by Tofthagen et al. (2012) evaluated the risk factors for falls in a 
group of patients with CIPN.  The participants received paclitaxel, docetaxel, oxaliplatin, or 
cisplatin and reported at least one symptom of CIPN. Tofthagen and colleagues found that fallers 
received higher cumulative doses of chemotherapy and a higher number of neuropathic 
symptoms as noted by higher score on the Chemotherapy Induced Peripheral Neuropathy 
Assessment Tool self-report questionnaire as a whole, as well as on both the symptom 
experience and interference items of the questionnaire.  The participants whom fell more also 
reported more severe muscle weakness, loss of balance, and increased interference with walking 
and driving.  An interesting finding was that participants who received paclitaxel or docetaxel 
were more likely to have fallen then those who received a platinum-based agent, such as 
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okaliplatin.  It was also interesting to note that Tofthagen and colleagues did not find a 
significant difference between fallers and nonfallers in terms of age, gender, stage of disease, or 
any other demographic characteristic (Tofthagen et al., 2012) 
Although the literature often generally cites that cancer patients report functional 
impairments, such as difficulties in walking, there is limited research examining specific gait 
parameters deficits.  Gait parameters are significant because research shows that spatiotemporal 
gait characteristics, such as cadence, stride length, swing, double support, stride length 
variability, and swing time variability, may be indicators of risk for falling.  Specifically, 
research indicates that slower gait speeds, decreases in step length, and increases in double 
support times may increase the risk of falling (Toulotte et al., 2006; Verghese et al., 2009).  
Similar to individuals with CIPN, aging will result in desensitization of motor units, as well as 
decreased perceptions of high-frequency vibrations, touch, proprioception, and pressure stimuli, 
indicating a disturbed somatosensory system (Prince et al., 2007).  
More current research has also shown that cancer patients may display a decrease in 
postural stability as a result of somatosensory changes that occur as a result of taxane 
chemotherapy (Tofthagen et al., 2012; Wampler et al., 2007).  Specifically, Wampler and 
colleagues (2007) conducted a prospective study that evaluated postural stability of women who 
received paclitaxel or docetaxel for treatment of breast cancer and compared them to matched 
health controls.  Because vision acuity plays a role in postural control, as well as in the 
neurological and visual system, inclusion criteria required participants to have a corrected low-
contrast visual acuity better than 20/60 and corrected high-contrast visual acuity better than 
20/40 (Wampler et al., 2007). 
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The participants in both the breast cancer and healthy control groups completed one 
testing session each.  To establish intrarater reliability, women in the breast cancer group 
returned and repeated all tests within 1 week of initial testing.  The participants in the breast 
cancer group were tested within 30 days of completing the final treatment of taxane infusion.  
Testing included several quantitative peripheral neuropathy measures, which included the total 
neuropathy score, the modified neuropathy score, quantitative touch thresholds, quantitative 
vibration thresholds and nerve conduction studies (Wampler et al., 2007). 
Several measures were used to assess postural control.  Center of pressure (COP) data 
were collected using a Kistler force plate to assess stability under four static positions: eyes open 
with head straight, eyes open with head back 40°, eyes closed with head straight, and eyes closed 
with head back 40°.  The NeuroCom Sensory Organization Test (SOT) was used to assess 
dynamic postural stability by way of a composite equilibrium score and a mean equilibrium 
score.  The SOT required the participants to stand as steady under six different conditions.  Three 
trials were performed for each condition.  The six conditions challenged the sensory system and 
increased in difficulty.  The first condition required the participants to keep their eyes open on a 
stable platform and a nonmoving visual surround.  The tests then progressed by removing visual 
feedback (by closing eyes), altering visual feedback (by moving the surround), or altering 
somatosensory feedback (rotating the platform in the sagittal plane).  The calculated equilibrium 
score represented the amount the participant swayed during the various conditions.  Also 
included was the Timed Up and Go (TUG) test, which has been established as a clinical measure 
of balance that assesses the relationships between the various measures of postural control 
(Wampler et al., 2007). 
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Wampler and colleagues (2007) found that the breast cancer patients treated with taxane 
chemotherapy experienced a mild yet significant peripheral neuropathy and a significant increase 
in mean TUG scores when compared to the healthy controls.  Furthermore, the participants with 
breast cancer displayed poorer static and dynamic postural control, especially during the 
conditions that required the participants to close their eyes, which required the participants to 
increasingly rely on their somatosensory and vestibular input for postural stability.  Wampler and 
colleagues (2007) concluded that women treated with taxanes may experience significant 
changes in postural stability as a result of their treatment, which may cause the neurotoxic of 
effect of taxane on the somatosensory systems and the subsequent changes that occur as a result 
of the neurotoxicity.  Furthermore, it was noted that while the severity of the peripheral 
neuropathy experienced by the participants in this study was mild, the COP velocities, as 
measured by the force plate, as well as their SOT scores from their first three conditions, were 
comparable to diabetic individuals diagnosed with severe neuropathy.  (Wampler et al., 2007).  
An additional interesting finding from the study conducted by Wampler and colleagues 
(2007) was that the modified TNS was moderately correlated with the total SOT score (r = -.66, 
p = .02) and explained just 44% of the variance in SOT scores.  This suggested that other 
pathological changes may be occurring as the result of chemotherapy and may contribute to 
postural instability (Wampler et al., 2007).   Tofthagen and colleagues (2012) suggested that it is 
important to note that other factors may contribute as well.  Treatment-related side effects, such 
as fatigue, generalized weakness, atrophy, anemia, and poor performance status, may also 
increase fall risk in those who undergo chemotherapy for treatment of cancer.  Generalized 
weakness may be the result of anemia, fatigue, and muscle weakness.  Anemia, which is a 
common side effect of cancer treatment, reduces the amount of red blood cells in the body and 
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thus reduces the oxygen-carrying capability.  This may result in tiredness and fatigue, which may 
be primary factors in fall incidences (Tofthagen et al., 2012). 
Although there has been a minimal amount of research done with respect to the 
mechanisms of falls often reported by cancer patients, the effects that peripheral neuropathy has 
on gait have been well documented within the diabetic population.  Specifically, it has been 
demonstrated that individuals with diabetic peripheral neuropathy generally display a gait that is 
more conservative and may be characterized by slower walking velocities and smaller step sizes 
(Paul et al., 2009; Wrobel et al., 2009).  Furthermore, as many as 62% of diabetics with 
peripheral neuropathy may fall (Wallace et al., 2002).   
Similar to chemotherapy-induced peripheral neuropathy (CIPN), diabetic peripheral 
neuropathy (DPN) targets both sensory and motor fibers and is progressive in nature.  Large- and 
small-diameter nerve fibers are affected, resulting in attenuated sensory nerve conduction, which 
includes large fiber thresholds for vibration and joint positions, as well as neurogenic atrophy 
due to axonal degeneration of motor fibers (Andersen et al., 1997; Dyck & Thomas, 1999; Horak 
et al., 2002) 
Patients with DPN may experience symptoms that are sensory in nature and may include 
burning, tingling, shooting (“electric shock”), lancing (stabbing), and numbness.  Symptoms may 
be present in both the upper and lower extremities and follow the “glove and stocking” 
distribution pattern, in which symptoms may initially present in the toes and fingers and progress 
proximally.  Individuals may also experience motor deficits, characterized by weakened muscles, 
particularly in the lower extremity.  DPN may also be the result of disruptions in the anatomy 
and function within the somatosensory system, which may be caused by endoneurial hypoxia 
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brought on by poor oxygen diffusion to the small blood vessels of the lower limbs (Tesfaye & 
Selvarajah, 2011).  
The pathophysiological mechanisms of DNP are not completely understood but may be 
related to the intermittent hyperglycemic damage of neurons that may increase the spontaneous 
C-fiber firing, which may be the result of remodeling of voltage-gated ion channels 
(Shankarappa et al., 2011).  Additionally, several other mechanisms have been postulated, such 
as changes in the disruption and expression of calcium and sodium channel, altered expression of 
neuropeptides and peripheral blood flow, atrophy, and degeneration to axons, damage to small 
fibers. Lastly, possible mechanisms may also include an increase in oxygen-free radicals, which 
cause oxidative stress and ischemia of nerves, mitochondrial disruptions, and reduced 
intraepidermal nerve fiber density and autonomic dysfunction (Kaur, Pandhi, & Dutta, 2011; 
Tesfaye & Selvarajah, 2011).  It has also been proposed that DPN is caused by endoneurial 
hypoxia brought on by poor oxygen diffusion to the small blood vessels of the lower limbs.  
Despite the uncertainty in pathophysiology, it is clear that peripheral neuropathy affects both 
sensory and motor fibers and is progressive in nature.  Large- and small-diameter nerve fibers are 
affected, resulting in attenuated sensory nerve conduction, which includes large-fiber thresholds 
for vibration and joint positions.  Small-fiber thresholds for pain and temperature are also 
affected (Dyck & Thomas, 1999; Horak et al., 2002). 
In addition to a decrease in nerve conduction information resulting in attenuated afferent 
and proprioceptive information, individuals with diabetic peripheral neuropathy also exhibit 
weakened knee and ankle muscle strength caused by neurogenic atrophy due to axonal 
degeneration of motor fibers (Andersen et al., 1997; Thomas & Tomlinson, 1993).  There is a 
significant decrease in muscle compartment cross-sectional area in both the proximal and distal 
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levels of the lower leg, resulting in impaired ankle dorsiflexors and plantarflexors (Andersen et 
al., 1997). 
Thus, individuals with DPN often display altered gait patterns, which may be 
characterized as slower, with shortened stride lengths and increased base widths, stride times, 
and double support times compared to age-matched controls (Allet et a., 2008; Paul et al., 2009; 
Wrobel et al., 2009).  The altered gait patterns may be due to the impaired proprioceptors and 
sensorimotor functions, which negatively affect the afferent feedback that is necessary to 
successfully modulate locomotion (Andersen et al., 1997; Dyck & Thomas, 1999; Horak et al., 
2002; Shankarappa et al., 2011).   
Individuals with diabetic peripheral neuropathy may display gait patterns characterized 
by slower speeds, shortened stride lengths, greater double support times, decreased ankle 
moments and powers, and decreased vertical and anterior–posterior ground reaction forces.   
Dingwell and Cavanagh (2001) investigated if these changes also resulted in locomotor 
variability, as increased locomotor variability is associated with increase incidences of falls.  
Participants included 14 diabetic individuals with significant neuropathy, as determined by 
Semmes-Weinstein filaments and a biothesiometer for vibration testing.  Participants were 
compared to 12 gender-, age-, height-, and weight-matched healthy controls (Dingwell & 
Cavanagh, 2001).   
Three strain gauge electrogoniometers were placed across the approximate joint centers 
of the hip, knee, and ankle of the right leg to measure sagittal plane motion.  To measure upper-
body dynamic stability, a triaxial accelerometer was attached to the base of the sternum to 
measure accelerations of the upper body in the anterior–posterior, vertical, and mediolateral 
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directions.  Each participant walked around a 200-m open-level indoor walking track at a natural 
pace.  Data were collected at 66.7 Hz (Dingwell & Cavanagh, 2001).   
Dingwell and Cavanagh (2001) found that the participants with peripheral neuropathy 
walked slower and took smaller steps compared to the control group.  Furthermore, the 
participants with peripheral neuropathy displayed significant increases in locomotor variability, 
and variability in the gait cycle was most highly correlated with falls.  Specifically, as variability 
increased, fall risk increased (Dingwell & Cavanagh, 2001).  
The findings by Dingwell and Cavanagh (2001) have since been confirmed in various 
other studies.  Paul and colleagues (2009) evaluated gait parameters of individuals with diabetic 
peripheral neuropathy (DPN) with individuals without DPN.  Of the 30 participants recruited, 15 
had DPN whereas the remaining 15 did not have DPN.  Paul et al. used the GAITRite walkway 
to evaluate various spatiotemporal parameters, such as step length and duration, duration of 
single and double support, velocity, and cadence.  The primary outcome was gait velocity.  For 
all of the gait variables measured, Paul and colleagues found that there was a statistically 
significant difference in gait parameters within individuals with DPN.  Specifically, individuals 
with DPN had significantly slower walking velocities, as well as shorter step length, but longer 
step times.  Individuals with DPN also displayed greater double support times and a slower 
cadence compared to individuals without DPN (Paul et al., 2009).  
Furthermore, Camargo et al. (2015) investigated the relationships between balance, ankle 
muscle strength, and spatiotemporal gait parameters in individuals with diabetic peripheral 
neuropathy.  The spatiotemporal gait parameters were evaluated by recording the time it took the 
participants to walk predetermined distances during self-selected walking speeds and maximal 
walking speeds.  Balance was evaluated using the Timed Up and Go (TUG) test. Compared to 
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healthy controls, individuals with DPN displayed significantly different spatiotemporal gait 
parameters and scores on the TUG test.  Specifically, individuals with DPN had shorter step 
lengths and slower cadence and gait speeds in both self-selected walking speed and maximal 
walking speed.  Results also indicated the individuals with DPN took greater amounts of time to 
perform the test, suggesting DPN individuals display functional deficits when ambulating 
(Camargo et al., 2015).  
Wuehr and colleagues (2014) evaluated the influence of peripheral neuropathy on 
walking patterns of 18 neuropathic individuals compared to age-matched controls.  The 
participants presented with significant peripheral neuropathy in their legs and feet as a result of 
various etiologies that consisted of type 2 diabetes, vitamin B12 deficiency, ethyl toxicity, and 
idiopathic peripheral neuropathy.  Walking velocity, as well as cadence, base width, stride 
length, stride time, double support time, double support time percentage, swing time percentage, 
and stance time percentage, were analyzed for each trial and leg separately using the GAITRite 
system.   
Wuehr and colleagues (2014) found that peripheral neuropathy directly affected gait 
variability between strides in both the mediolateral plane (base width) and fore–aft plane (stride 
time and stride length).  Specifically, individuals with peripheral neuropathy displayed 
significant variability in heel strike magnitudes, regardless of walking speed, which is significant 
considering mediolateral adjustments are primarily controlled by integrated sensory feedback 
(Wuehr et al., 2014).  Fore–aft locomotion, which is thought to be stabilized by biomechanical 
regulation, should not be affected by a deficit in the sensory system.  However, individuals with 
peripheral neuropathy, and thus deficient peripheral sensory systems, displayed significant 
variability in both stride length and stride time.  Variability was more present at slower walking 
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speeds, which is when locomotion is relies highly on active sensory feedback (Wuehr et al., 
2014).   
In summary, many patients who receive chemotherapy as part of their treatment for 
cancer are likely to experience CIPN in one form or another, which can cause a variety of 
debilitating symptoms due to peripheral nerve toxicities caused by the chemotherapy agents 
(Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007).  Specifically, chemotherapy agents 
may disrupt axonal transport, resulting in diminished or absent deep tendon reflexes, 
hyperesthesias, hypoesthesias, paresthesias, pain, loss of temperature and vibration sense, loss of 
proprioception, and motor neuropathy (Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007).  
Cancer survivors who receive chemotherapy for cancer treatment may experience a disruption to 
the somatosensory systems which may negative effect the sensory feedback that is necessary to 
produce a coordinated and balanced gait (Magill & Anderson, 2013; Murillo et al., 2008; 
Visovsky et al., 2007; Wilkes, 2007).   Research indicates that cancer survivors who have 
undergone chemotherapy report gait disturbances and higher incidences of falls (Bylow et al., 
2008; Gewandter et al., 2013; Mohile et al., 2009, 2011; Stone et al., 2012; Tofthagen et al., 
2012; Wampler et al., 2007).  Although the literature has not evaluated specific changes in 
spatiotemporal gait parameters in cancer patients, previous research indicates that individuals 
afflicted with peripheral neuropathy as a result of various etiologies will display altered gait 
patterns characterized by smaller step and stride lengths, wider step widths, increased double 
support times, and slower walking speeds (Dingwell & Cavanagh, 2001; Toulotte et al., 2006; 
Verghese et al., 2009; Wuehr et al., 2014).  Furthermore, individuals with peripheral neuropathy 
will display increased variability within these same parameters, which is significant considering 
that increased variability is associated with increased falls (Dingwell & Cavanagh, 2001; Maki, 
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1997).  As a result, patients experiencing peripheral neuropathy, regardless of the etiology, 
experience fall rates that are higher than individuals without peripheral neuropathy.  However, 
investigation of changes within spatiotemporal gait parameters has provided insight as to the 
changes in gait that individuals with peripheral neuropathy due to diabetes and vitamin 
deficiencies.  Research has not investigated changes within the spatiotemporal gait parameters of 
cancer patients experiencing CIPN.  Therefore, considering the common pathophysiologies of 
peripheral neuropathy between diabetic peripheral neuropathy and chemotherapy-induced 
peripheral neuropathy and evaluating spatiotemporal gait patterns such as stride length, cadence, 
and velocity within individuals diagnosed with CIPN may provide insight into the gait 
interference and incidences of falling that patients with CIPN have reported within the literature.   
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Chapter III 
METHODS 
Cancer survivors who receive chemotherapy for cancer treatment may experience a 
disruption to the somatosensory systems, which may negatively affect the sensory feedback 
which aides in the coordinated and balance required in gait (Magill & Anderson, 2013; Murillo 
et al., 2008; Visovsky et al., 2007; Wilkes, 2007).   Research indicates that cancer survivors who 
have undergone chemotherapy report gait disturbances and higher incidences of falls (Bylow et 
al., 2008; Gewandter et al., 2013; Mohile et al., 2009, 2011; Stone et al., 2012; Tofthagen et al., 
2012; Wampler et al., 2007).  Although the literature has not evaluated specific changes in 
spatiotemporal gait parameters, research has indicated an association between cadence, stride 
length, swing, double support, stride length variability, and swing time variability.  Specifically, 
research indicates that slower gait speeds, decreases in step length, and increases in double 
support times may increase the risk of falling (Toulotte et al., 2006; Verghese et al., 2009).  
Thus, evaluating spatiotemporal gait patterns within individuals diagnosed with CIPN who are at 
a risk for falls may provide insight into the gait interference that increases the risk of falling as 
reported in the literature by patients with CIPN.   
Therefore, the purpose of this study is to assess whether chemotherapy-induced 
peripheral neuropathy is associated with spatiotemporal gait adaptations in posttreatment adult 
cancer survivors when compared to healthy, disease-free, age- and morphologically matched 
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Participants 
Sixteen participants between the ages of 50 and 70 were recruited for participation.  Eight 
of the participants had a histologically confirmed stage 2–3 breast or colorectal cancer diagnosis 
with a confirmed treatment plan consisting of taxane- or oxaliplatin-based chemotherapy as 
confirmed by an oncologist.  Participants also had a confirmed diagnosis of chemotherapy-
induced peripheral neuropathy according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0.   
Subjects were excluded if they had a history of peripheral neuropathy (i.e., hereditary 
peripheral neuropathy associated with nutritional agents and paraneoplastic), known peripheral 
neuropathy, or diseases that may contribute to peripheral nerve damage, such as diabetes, renal 
insufficiency, alcohol abuse, vitamin B12 deficiency, HIV, and vasculitis.  Subjects were 
excluded if they had central or peripheral neurologic disease, brain or spinal cord metastases, 
orthopedic problems that affect balance, or vestibular system or visual disease.  Subjects were 
excluded if they had corrected low-contrast visual acuity worse than 20/60 and a corrected high-
contrast visual acuity worse than 20/40.  Subjects, who had participated in regular exercise, as 
defined as 150 min of light-to-moderate intensity exercise per week over the past year, were 
excluded from this trial.  Subjects were also excluded if they used a walking aide. 
Design 
 This study was a quasi-experimental design.  
Variables 
 The variables included both spatial and temporal gait parameters.  The spatial gait 
parameters consisted of step length and base of support.  Step length was measured from the heel 
center of the current footprint to the heel center of the previous footprint on the opposite foot, by 
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the GAITRite walking system.  H-H base of support, or base width, was measured as the vertical 
distance from the heel center of one footprint to the line of progression formed by two footprints 
of the opposite foot, as measured by the GAITRite walking system. 
 The temporal gait parameters consisted of velocity, step time, swing time, single support 
time, and double support time.  Velocity was defined as dividing the distance traveled by the 
ambulation time and was expressed in centimeters per second (cm/sec).  Step time was defined 
as the time in seconds elapsed from first contact of one foot to first contact of the opposite foot.  
Swing time was initiated with the toe off and ended with the heel strike.  It was defined as the 
time elapsed between the last contact of the current footfall to the first contact of the next footfall 
on the same foot and was expressed in seconds (s).  Single support was defined as the time 
elapsed between the last contact of the current footfall to the first contact of the next footfall of 
the same foot and was measured in seconds (s).  Swing time is equal to the single support time of 
the opposite foot.  Lastly, double support time was defined as the period when both feet are on 
the floor.  Initial double support occurs from the heel contact of one footfall to the toe-off of the 
opposite footfall and is measured in seconds (s).  Fall risk was defined as the time it took to 
complete the Timed Up and Go test.  Research suggested that a time of greater than 10.7 s 
indicated risk for falls (Jernigan et al., 2012).  
Measurements 
The GAITRite system was used to measure all spatio temporal parameters of gait. It is an 
electronic pathway that is 8.2 m in length.  Through an interface bale, the electronic pathway 
connects to a personal computer.  The electronic pathway is made up of a series of sensory pads 
that are inserted in grid formation between a layer of vinyl (top cover) and foam rubber (bottom 
cover).  The active area is 61 cm wide and 732 cm long.  The sensors are placed 1.27 cm apart 
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and are activated by mechanical sensors.  There are a total of 27,648 sensors.  Data from the 
activated sensors are collected by a series of onboard processors and transferred to the computer 
through a serial port.  The sampling rate of the system is 8 Hz.  Visually, the walkway resembles 
a carpet runner and is portable (Webster, Wittwer, & Feller, 2004).   
Fall risk was assessed using the valid and reliable Timed Up and Go test (TUG), which is 
a mobility test used to measure basic mobility skills (Webster, Wittwer, & Feller, 2004).  The 
measurement outcome for the TUG is the time it takes to rise up out of a chair, walk 3 m away 
from the chair, walk 3 m back to the chair, and return to the seated position.  The time it takes to 
complete this task is recorded.  Previous research indicates that a time of greater than 10.7 s 
indicates risk for falls (Jernigan et al., 2012).  
Procedures 
Potential subjects were recruited through the placement of an Institutional Review Board 
(IRB)–approved advertisement flyer (see Appendixes A and B) on bulletin boards located 
throughout the Seton Hall University (SHU) community, as well as the surrounding SHU 
community.  Participants were also recruited from Saint Michael’s Medical Center, located in 
Newark, NJ.  See Appendix E for the research flyer.  A snowballing sampling technique method 
was used to recruit participants (Portney & Watkins, 2009).   
Upon seeing the study research flyer, potential subjects contacted the primary 
investigator (PI) by either the e-mail address or phone number listed on the flyer (see Appendix 
B).  Upon being contacted, the PI scheduled a meeting with the potential subject at the South 
Orange Campus of Seton Hall University, 400 South Orange Avenue, South Orange, New 
Jersey, in Corrigan Hall Room 67 (Functional Human Performance Lab) in order to review the 
inclusion and exclusion criterion for participation.  The PI also met participants at the Cancer 
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Center at Saint Michael’s Medical Center, which was a second testing site.  The subjects were 
instructed to wear a T-shirt or sweatshirt, shorts or sweatpants, and a pair of comfortable walking 
shoes or sneakers to the testing sessions.  Upon arrival to the testing session site, subjects were 
required to read an informed consent form.  Subjects were given the opportunity to ask 
questions.  If, after reviewing the consent forms and asking any related questions, the potential 
subjects were still willing to volunteer to participate, they were required to sign the consent 
forms and were advised that they could withdraw from the study at any time. 
Following the signing of the informed consent forms, the PI administered the prescreen 
tool (see Appendix C) to those who met the study inclusion and exclusion criteria.  The subjects’ 
responses were recorded.  An answer of yes to any of the questions indicated that the subject did 
not fit the inclusion and exclusion criteria and thus could not participate in the present study.  If 
the subject did not qualify for participation, the subject was thanked for being willing to 
volunteer.  Those subjects who met the study inclusion criteria proceeded to the data collection 
portion of the study. 
Data collection began with the completion of the top portion of the Participant Data 
Collection Sheet (see Appendix D), which included the subject’s cancer diagnosis, name of the 
chemotherapy agent received, age, sex, height, and weight. Prior to the collection of the 
spatiotemporal parameters of gait using the GAITRite system and risk of falls by the Timed Up 
and Go test, subject height and right/left leg length were measured (from the greater trochanter to 
the floor) using a standardized, flexible cloth tape.  These data were required by the GAITRite 
software.   
Next, following standard protocol, the Timed Up and Go test was performed to assess fall 
risk.  The Timed Up and Go test required the subjects to raise their body out of a chair, walk 3 m 
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down a hallway, turn around, walk 3 m back to the chair, and sit back down in the chair.  To set 
up the test, a 3-m (9.8-ft.) walkway was measured and marked on the floor using colored tape.  
The floor of the walkway was clear of any objects.  A standard-height chair (seat height, 46 cm; 
arm height, 67 cm) was positioned at the beginning of the walkway.  The subjects began by 
sitting on the standard chair, placing their back against the chair, and resting their arms by their 
sides.   
The PI demonstrated the test prior to the subject performing the test.  After the 
demonstration, PI instructed the subject to walk at a self-selected pace.  When the subject was 
ready, the PI said “Go,” indicating to the subject to get up out of the chair, walk the 3-m distance 
away from the chair, walk the 3-m distance back to the chair and sit back down.  The stopwatch 
was started upon the “Go” command from the PI and was stopped when the subject’s butt made 
contact with the seat upon sitting back down.  The time it took to complete the test was recorded 
on the Individual Participant Data Collection Sheet (see Appendix B).  Fall risk was indicated by 
a timed score of greater than 10.7 (Jernigan et al., 2012)  
Jernigan and colleagues (2012) suggested that because in the clinical setting, sensitivity is 
the most important measure, as high sensitivity corresponds to more true positives and fewer 
false negatives.  The Timed Up and Go test is a good test to assess fall risk due to its high 
sensitivity of 90%, 88.5% specificity, and high diagnostic accuracy at 88.9% when a modified 
cutoff score is applied.  Subjects who volunteered to be in the control group were also assessed 
for fall risk.  
After the completion of the Timed Up and Go test, the GAITRite was used to compute 
the spatiotemporal gait parameters (step length, step time, and walking speed).  Before initiating 
walking on the GAITRite, the PI set up the location.  For each trial, subjects were instructed to 
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initiate walking from a non sliding standing spot mat located at the midpoint of the start line 
placed 2 m before the beginning edge of the GAITRite carpet.  This allowed walking to be 
initiated from the same location at every trial and permitted a steady state of ambulation to be 
achieved prior to stepping on the GAITRite walkway.  The subjects were informed to negotiate 
the entire length of the 5.18-m GAITRite carpet walkway at a steady pace while looking straight 
ahead.  Three trials were performed.   
Data Analysis 
The present study contained two groups: a control group, which consisted of healthy, 
disease free, age and morphologically matched controls, and an intervention group, which 
consisted of cancer survivors diagnosed with CIPN.  The independent variable was the presence 
of CIPN.  There were multiple dependent variables, which included the participants’ TUG score 
and spatiotemporal gait parameters obtained from the GAITRite.  Thus, the research question 
was answered by using a one-way MANOVA comparing each of the spatial and temporal 
variables between the two groups.  An alpha level of 0.05 was used (Field, 2009).  
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Chapter IV 
RESULTS 
The purpose of this study was to investigate if changes exist in the spatiotemporal gait 
parameters of cancer patients who have completed chemotherapy for the treatment of cancer 
compared to age and morphological matched controls.  A total of 16 subjects participated in the 
present study.  Of the 16 subjects, 8 had CIPN, and the remaining 8 subjects were the age and 
morphologically matched controls.   
Table 1 indicates that both of the groups had 6 females and 2 males.  Table 2 indicates 
that the mean age of the CIPN participants was 61.38 years (SD = 7.24) and the mean age of the 
control participants was 62.25 years (SD = 3.77).  Table 2 shows that the mean weight of the 
CIPN participants was 76.45 kg (SD = 18.48), whereas the mean weight of the control 
participants was 72.42 kg (SD = 8.88).  Table 3 indicates that 5 of the participants had breast 
cancer and 3 participants had colon cancer.  Of the types of chemotherapy received, 1 participant 
received pacelitaxel, 4 participants received taxanes, and 3 participants received oxaliplatin. 
Table 4 indicates that age was normally distributed for CIPN D (7) = .224, p > .05 and 
control, D (7) = .122, p > .05.  Table 4 shows that weight was normally distributed for CIPN D 
(7) = .584, p> .05 and control, D (7) = .117, p> .05.  Table 4 also denotes that height was 
normally distributed for CIPN D (7) = .832, p> .05 and control D (7) = .936, p> .05.  Lastly, as 
indicated in table 5, BMI was normally distributed for CIPN D (5) = .901, p> .05 and control, D 
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Table 1 
Participant Gender 
 Participant type N 




Participant type N Mean Std. deviation Std. error mean 
Age (yrs.) CIPN 8 61.38 7.42 2.63 Control 8 62.25 3.77 1.33 Weight (kg) CIPN 8 76.45 18.48 6.53 Control 8 72.42 8.88 3.14 Height (cm) CIPN 8 158.05 14.35 5.07 Control 8 167.90 9.44 3.34 BMI (kg/m2) CIPN 8 27.71 6.34 2.24 Control 8 24.85 2.37 .84  
Table 3 
Cancer Participant Descriptive 
  Chemotherapy type 
Cancer type n Paclitaxel Taxane Oxaliplatin 
Breast Cancer 5 1 4  
Colon Cancer 3   3 
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Table 4 
Evaluating Descriptive Data for Normal Distribution 
 Participant type 
Kolmogorov-Smirnov Shapiro-Wilk  Statistic df Sig. Statistic df Sig. 
Age CIPN .159 8 .200 .888 8 .224 Control .267 8 .097 .861 8 .122 Weight (Kg) CIPN .189 8 .200 .937 8 .584 Control .223 8 .200 .859 8 .117 Height (cm) CIPN .289 8 .048 .832 8 .062 Control .157 8 .200 .936 8 .576 BMI CIPN .210 8 .200 .901 8 .296 Control .265 8 .103 .884 8 .205  
Table 5 indicates that there was equal variability with age, F (1, 14) = 4.01, p > .05.  
Table 5 shows that the assumption of homogeneity of variance for weight had been violated, F 
(1, 14) = 6.59, p < .05.  Table 5 shows that there was equal variability with height, F (1, 14) = 
.145, p > .05, but homogeneity of variance was not violated.  Lastly, as displayed in Table 5, the 
assumption of homogeneity of variance for BMI had also been violated, F (1, 14) = 10.10, p < 
.05. 
Table 5 
Evaluating the Descriptive Data for Homogeneity of Variance 
 Levene statistic df1 df2 Sig. 
Age (years) Weight (kg) Height (cm) BMI 
4.01 1 14 .065 6.59 1 14 .022 .145 1 14 .709 10.10 1 14 .005  
An independent t test was used to evaluate if the participant characteristics of the CIPN 
group were significantly different or similar to the participant demographics of the control group.  
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As four independent t tests were run on the same data, a Bonferroni correction was applied to 
reduce the risk of making type 1 error (Field, 2009).  As indicated in Table 6, there was no 
significant difference in age, t (14, = –.297, p > .05 or weight, t (10.071) = .556, p > .05, between 
the two groups.  Table 6 also denotes that there was no significant difference in height, t (14) = -
1/622, p > .05, or BMI, t (8.913) = 1.196, p > .05, between the two groups.  Therefore, there was 
no significant differences between the participant characteristics of the two groups other than the 
presence of chemotherapy-induced peripheral neuropathy.   
Table 6 
Independent t Test to Compare Descriptive Data Means 
 
t test for equality of means 
t df Sig. (2-tailed) 
Age Equal variances assumed -.297 14 .771 Equal variances not assumed -.297 10.385 .772 Weight (kg) Equal variances assumed .556 14 .587 Equal variances not assumed .556 10.071 .590 Height (cm) Equal variances assumed -1.622 14 .127 Equal variances not assumed -1.622 12.100 .131 BMI Equal variances assumed 1.196 14 .251 Equal variances not assumed 1.196 8.913 .262 
  With the results of the independent t test indicating that two groups were the same with 
regard to their demographic characteristics, a one-way MANOVA was conducted to determine if 
significant differences exist between the dependent variables.  Before a one-way MANOVA was 
ran, the assumptions for the test were first tested.  The assumptions tested consisted of 
multivariate normality, the linear relationship between the dependent variables, the homogeneity 
of variance–covariance matrices, and multicollinearity (Field, 2009) 
The first assumption tested was multivariate normality by use of the Shapiro-Wilk test 
(Field, 2009).   
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Table 7 
Assessing Normal Distribution of Gait Parameters 
 
Participant type 
Kolmogorov-Smirnov Shapiro-Wilk  Statistic df Sig. Statistic df Sig. 
TUG CIPN .340 8 .007 .643 8 .001 Control .183 8 .200* .899 8 .284 Velocity CIPN .184 8 .200* .950 8 .708 Control .203 8 .200* .911 8 .358 R_Step_Time CIPN .218 8 .200* .784 8 .019 Control .179 8 .200* .903 8 .308 R_Step_Length CIPN .291 8 .045 .791 8 .023 Control .202 8 .200* .912 8 .372 R_HH_Base_Support CIPN .141 8 .200* .945 8 .658 Control .219 8 .200* .943 8 .642 R_Swing_Time CIPN .172 8 .200* .937 8 .582 Control .272 8 .083 .820 8 .046 R_Single_Support_Time CIPN .228 8 .200* .881 8 .194 Control .185 8 .200* .955 8 .761 R_Double_Support_Time CIPN .213 8 .200* .947 8 .679 Control .197 8 .200* .896 8 .265  
Table 7 indicates that the data for the TUG test for the CIPN group, D (7) = .643, p < .05, 
were not normally distributed.  But the TUG data for the control group were normally 
distributed, D (7) = .899, p > .05.  Velocity data for the CIPN group, D (7) = .950, p > .05, as 
well as data for the control group, D (7) = .911, p > .05, were normally distributed. Table 7 
depicts that data for the right step time of the CIPN group, D (7) = .784, p < .05, were not 
normally distributed, whereas data for the control group was normally distributed, D (7) = .903, 
p > .05.  Furthermore, CIPN data for base step length, D (7) = .791, p < .05, were not normally 
distributed, whereas data for control were normally distributed, D (7) = .912, p > .05.  Base of 
support data for both the CIPN group, D (7) = .945, p > .05, and control group, D (7) = .943, p > 
.05, were normally distributed.  Swing time data for the CIPN group, D (7) = .937, p > .05, were 
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normally distributed, whereas swing time data for the control group were not normally 
distributed, D (7) = .820, p < .05.  Table 7 indicates that single support time for the CIPN group, 
D (7) = .881, p > .05, and the control group, D (7) = .955, p > .05, were normally distributed.  
Lastly, Table 7 depicts that double support time data for the CIPN group, D (7) = .947, p > .05, 
and control group, D (7) = .896, p > .05, were both normally distributed.  Although Table 7 
indicates violations of the assumption of normal distribution, however, a one-way MANOVA 
was still conducted, as the test is robust enough (Field, 2009).  
The second assumptions tested was if there was homogeneity of variance-covariance 
matrices by use of the Leven’s test (Field, 2009).  Table 8 displays the results of Levene’s test, 
which assesses homogeneity of variance/covariance.  As indicated in Table 8, there was no 
significant difference in variability for TUG data, F (1, 14) = 3.84, p > .05.  Table 8 also 
indicates that velocity, F (1, 14) = 32.44, p > .05, and step time, F (1, 14) = 3.28, p > .05, also 
satisfied the assumption of homogeneity of variance/covariance.  
Table 8 
Leven Test for Homogeneity of Variance-Covariance 
 Levene statistic df1 df2 Sig. 
TUG Velocity R_Step_Time R_Step_Length R_HH_Base_Support R_Swing_Time R_Single_Support_Time R_Double_Support_Time 
3.84 1 14 .070 
2.55 1 14 .133 
3.28 1 14 .092 
4.00 1 14 .065 
2.58 1 14 .131 
2.56 1 14 .132 
.74 1 14 .403 
1.07 1 14 .319  
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Base of support, F (1, 14) = 2.58, p > .05, and swing time, F (1, 14) = 3.84, p > .05, also 
satisfied the assumption of homogeneity of variance/covariance.  Lastly, as depicted in Table 8, 
single support time F (1, 14) = .74, p > .05 and double support time, F (1, 14) = 1.07, p > .05, 
data also satisfied the assumption of homogeneity of variance/covariance (Field, 2009). 
The third assumption addressing a linear relationship between the dependent variables for 
each of the independent variables using scatterplot matrices (Field, 2009).  Figure 1 indicates that 
there was a linear relationship between TUG and velocity for the independent variables, thus 
satisfying the MANOVA assumption.  Figure 2 indicates that there was a linear relationship 
between step time and step length for the independent variables, thus satisfying the MANOVA 
assumption.   
 
          Figure 1. Linear relationship for TUG and velocity.             Figure 2. Linear relationship for step time and step length. 
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Figure 4. Linear relationship for single and double support time.  
Figure 3 indicates that there was a linear relationship between base of support and swing 
time for the independent variables, thus satisfying the MANOVA assumption.  Figure 4 indicates 
that there was a linear relationship between single and double support time for the independent 
variables, thus satisfying the MANOVA assumption.  
The last assumption test was multicollinearity by use of the Pearson’s correlation 
coefficient.  The dependent variables did not display a high level of correlation, which was 
indicated by a Pearson product value of .90 or higher (Field, 2009).  As indicated in Table 9, 
none of the dependent variables were highly correlated because all Pearson correlations were 
below 0.90.  Thus, the assumption was satisfied (Field, 2009).  
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Table 10 indicates the mean Timed Up and Go (TUG) time for the CPN participants was 
12.33 s (SD = 6.25), whereas the mean TUG time for the control was 6.62 s (SD = 1.10).  The 
CIPN group had a mean step time of .55 s per step (SD = .08), whereas the control had a mean 
step time of .52 s per step (SD = .02).  As displayed in Table 10, the mean step length for the 
CIPN group was 53.92 cm per step (SD = 23.55), whereas the mean step length for the control 
was 77.15 cm per step (SD = 5.28).  The CIPN group mean base of support was 8.77 cm (SD = 
3.00), whereas the control group had a mean base of support of 7.87 cm (SD = 1.97).  The mean 
swing time for the CIPN group was .44 s per step (SD = .04), whereas the mean swing time for 
the control group was .43 s per step (SD = .02).  The mean single support time for the CIPN 
group was .44 s per step (SD = .05), whereas the mean single support time for the control group 
was .43 s per step (SD = .03).  Lastly, Table 10 indicates that the mean double support time for 
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the CIPN group was .24 s per step (SD = .07), whereas the mean double support time for the 
control group was .18 s per step (SD = .07).   
Table 10 
Dependent Variable Descriptive Statistics 
 Participant type Mean Std. deviation N 
TUG(s) CIPN 12.33 6.25 8 Control 6.62 1.10 8 Total 9.48 5.24 16 Velocity CIPN 110.75 26.79 8 Control 147.79 11.69 8 Total 129.27 27.65 16 R Step Time CIPN .55 .08 8 Control .52 .02 8 Total .54 .06 16 R Step Length CIPN 53.92 23.55 8 Control 77.15 5.28 8 Total 65.53 20.39 16 R HH Base Support CIPN 8.77 3.00 8 Control 7.87 1.97 8 Total 8.32 2.49 16 R Swing Time CIPN .44 .04 8 Control .43 .02 8 Total .43 .03 16 R Single Support Time CIPN .44 .05 8 Control .43 .03 8 Total .44 .04 16 R Double Support Time CIPN .24 .07 8 Control .18 .04 8 Total .21 .07 16  
Next, a one-way MANOVA was performed to determine if a significant difference 
existed between the mean TUG and one or more of the spatiotemporal gait values.  A one-way 
MANOVA was performed due to having more than one dependent variable.  Table 10 displays 
the results of the one-way MANOVA. 
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 Table 11 indicates that there was no significant difference in TUG scores or 
spatiotemporal gait parameters between the control group and participants with chemotherapy-
induced peripheral neuropathy, F (8, 7) = 2.45, p > .05, partial η2 = .74. Pillai’s trace test 
statistics were used because, as indicated in Table 7, there were violations of the assumptions of 
normal distribution.  Therefore, due to the conservative nature of Pillai’s trace, it was the more 




Effect Value F Hypothesis df Error df Sig. 
Partial Eta Squared 
Intercept Pillai's Trace 1.00 2141.86 8.00 7.00 .00 1.00 Wilks' Lambda .00 2141.86 8.00 7.00 .00 1.00 Hotelling's Trace 2447.83 2141.86 8.00 7.00 .00 1.00 Roy's Largest Root 2447.83 2141.86 8.00 7.00 .00 1.00 Participant type Pillai's Trace .74 2.45 8.00 7.00 .13 .74 Wilks' Lambda .26 2.45 8.00 7.00 .13 .74 Hotelling's Trace 2.80 2.45 8.00 7.00 .13 .74 Roy's Largest Root 2.80 2.45 8.00 7.00 .13 .74 
 Table 12 displays the results of multiple analyses of variance run to determine if any of 
the dependent variables differed for the deponent variables.  Because 8 ANOVAs were run, a 
Bonferroni correction was applied, adjusting the alpha to decrease to risk of making a type 2 
error.  The original alpha level of .05 was divided by 8 to determine the new alpha level of .006.  
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Using the correct alpha level, only velocity was noted to be significantly different between the 
control group and CIPN group, F (1, 16) = 12.85, p = .003, partial η2 = .48.   
Table 12 displays the results of multiple Kruskal-Wallis H test, which was performed 
given that the data was not normally distributed.  Since 8 Kruskal-Wallis H test were performed, 
a Bonferroni correction was applied, adjusting the alpha to decrease the risk of making a type 2 
error.  The original alpha level of .05 was divided by 8 to determine the new alpha level of .006.  
Effect size was calculated using the equation,݊ଶ =  ுି௞ାଵ௡ି௞ , where H was the value obtained in the 
Kruskal-Wallis test, n² is eta squared, ‘k’ was the number of groups, and ‘n’ was the total 
number of observations (Tomczak & Tomczak, 2014). 
Table 12 
Kruskal-Wallis H Test Output 
 TUG Velocity R_Step_ Time R_Step_ Length 
R_HH_ Base_ Support R_Swing_ Time R_Single_ Support_Time R_Double_ Support_Time 
Chi-Square 11.29 7.46 .40 8.04 .54 .04 .00 3.19 df 1 1 1 1 1 1 1 1 Asymp. Sig. .001 .006 .529 .005 .462 .833 .958 .074  
Using the correct alpha level, velocity was found to be significantly different between the 
control group and CIPN group, X²(1) = 7.46 p = .006; n² = 0.43.  Step length was also found to 
be significantly different between the control group and CIPN group, X²(1) = 8.04, p = .005, n² = 
0.47.  Lastly, the TUG time was also found to be significantly different between the control 
group and the CIPN group, X²(1) = 11.29, p = .001; n² = 0.69.   
 












Figure 5. G-power analysis.  
As indicated in figure 5, a large partial eta squared lead to a large effect size (2.85).  
Additionally, it was found that the power for the present study was .87, which satisfied the .8 
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Chapter V 
DISCUSSION 
With screening measures and treatment options improving, the number of people 
surviving a cancer diagnosis is increasing (Siegel et al., 2012).  However, many cancer survivors 
are dealing with long-term physical and emotional side effects that negatively impact their health 
and overall quality of life (Rowland & Bellizzi, 2014).  A common functional impairment 
experienced by cancer patients who received chemotherapy is chemotherapy-induced peripheral 
neuropathy (CIPN) (Stubblefield et al., 2009).  It is estimated that the incidence rate of CIPN is 
30%–70% dependant up on various factors, such as the class of chemotherapy agent and/or the 
cumulative dosage of the agent (Mantyh, 2006).  Taxanes, such as paclitaxel, are commonly used 
to treat breast cancer, causing CIPN in 57%–83% of patients (Stubblefield et al., 2009).   
 Chemotherapy-induced peripheral neuropathy symptoms are often described as 
paraesthesia-like numbness and/or pain, which occurs in a stocking-and-glove distribution 
(Argyriou et al., 2012).  Cancer patients with CIPN often report difficulties in walking, in that 
they feel unsteady and have a reduced sense of balance (Grisold, Cavaletti, & Windebank, 2012; 
Visovsky & Daly, 2004; Wampler et al., 2007).  The impaired balance and gait reported by 
cancer patients has been linked to increased fall risk, potentially causing significant limitations in 
the ability to perform tasks of daily living (Quasthoff & Hartung, 2002; Stubblefield et al., 2009; 
Tofthagen et al., 2012; Windebank & Grisold, 2008).  However, little is known about the specific 
gait impairments that may be caused by CIPN and if these gait impairments contribute to the 
increase in fall risk (Wampler et al., 2007).  Furthermore, little is known about the compensation 
strategies employed by cancer patients with CIPN to manage these functional deficits.  
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Therefore, the purpose of this study was to investigate possible changes in spatiotemporal gait 
patterns of cancer patients with CIPN.   
 In the present study, it was found that CIPN subjects gait velocity (110.75 cm/s) was 
significantly slower than control subject’s walking velocity (147.79 cm/s).  Furthermore, the step 
length of those with CIPN (53.92 cm) was significantly shorter than the step length of the control 
subjects (77.15 cm).  This studies finding that individuals with CIPN do have slower gait 
velocities is noteworthy because it supports a study done by Verghese et al. (2009) who found 
that individuals with gait speeds between 70 and 100 cm/s were more like to fall then individuals 
with gait speeds above 100 cm/s.  Furthermore, Verghese et al. (2009) found that a decrease in 
gait velocity by 10 cm/s increased fall risk by 7% and thus concluded that gait velocity is a 
simple and quick way to assess fall risk. 
Moreover, the CIPN participants in this current study had a gait velocity of 110. 75 cm/s 
(SD = 26.79), which is above the upper threshold 100 cm/s that Verghese et al. (2009) found to 
predict falls.  However, the participants in the present study had a mean age of 61. 38 years (SD 
= 7.42), whereas the mean age of the participants in the study by Verghese et al. (2009) was 80.5 
years.  Thus, despite the age difference of approximately 20 years, the difference in gait velocity 
between those with CIPN and the participants in the study by Verghese et al. (2009) was 10 cm/s.  
This suggests that the presence of CIPN may negatively impact individuals’ gait to the extent that 
they will develop a gait pattern similar to that of someone who is 20 years their senior. 
Additionally, a decrease in gait velocity was found in this study and is concerning as 
decreased velocity has been found to be directly associated with an increase in fall risks, (Espy et 
al., 2010).  The mean Timed-Up & Go (TUG) time for those with CIPN was 12.33 seconds (SD 
= 6.25), which was significantly greater than the mean TUG time for the control group which 
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was 6.62 (SD = 1.10).  Moreover, the mean TUG time by those with CIPN was well above the 
score of 10.7 seconds which researchers suggest is indicative of fall risk (Jernigan et al., 2012).  
Therefore, the results further support that those with CIPN are at a higher risk of falling. 
Not only was there a significant difference in gait velocity in this study, but individuals 
with CIPN consistently displayed significantly shorter step lengths; with  a mean step length of 
53.92 cm, which was significantly shorter than the control step length of 77.15 cm.   
In the literature various clinical assessments are used to evaluate fall risk including the 
Timed-Up-and-Go (TUG). While the TUG test has demonstrated its clinical effectiveness in 
assessing fall risk, the TUG does not evaluate kinetic differences that are specific to the 
impairment that may be influence fall risk in all populations (Schulz et al., 2010). Thus 
researchers have used the Maximum Step Length (MSL) test which assesses both dynamic 
balance and leg strength.  Clinically, a decrease in the MSL test is associated with an increase 
decade of life and performance on clinical assessments that are used to predict falls; as MSL 
decrease, fall risk increases (Cho et al., 2004; Lindermann et al., 2003; Schulz et al., 2013).  
Research indicates that the majority of falls experienced by the elderly and individuals with 
diabetic peripheral neuropathy will have gait patterns that are consistent with   shortened step 
lengths (Paul, Ellis, Leese, McFadyen, McMurray, 2009; Shumway-Cook & Woollacott, 2012).  
Thus, the findings in the present study of decreased step length in individuals with CIPN can be 
associated with increased fall risk.  
While previous research suggest that peripheral nerve dysfunction results in lower 
extremity impairments and functional limitations, such as a decrease in gait speed, the findings 
of  the present study are not entirely consistent with previous research because previous research 
in diabetics with peripheral neuropathy suggested that in the presence of peripheral neuropathy, 
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gait patterns should undergo significant changes; in this study only gait velocity and step length 
were significantly different.  A plausible reason for the inconsistencies between the results of the 
present study and previous research may be due to several limitations.  First, the presence of 
CIPN was determined by the Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0, in which patients can simply report numbness and tingling; so, the extent of the 
damage to peripheral nerves was not quantified nor was the fiber types affected by the 
chemotherapy agents specified.  This is a significant limitation because the types of fibers 
affected by the chemotherapy agents may explain why only velocity was found to be 
significantly different.  While type Ia, type Ib, and type 2 fibers may be the primary fibers 
providing afferent feedback for the reflex arcs involved in gait mediation, these may not be the 
main fibers affected by the chemotherapy agents (Argyriou et al., 2012; Mantyh, 2006). 
In the literature it has been suggested that unmyelinated C fibers and myelinated Aδ 
fibers, which are sensory fibers called nociceptors, may in fact be the primary targets on which 
the chemotherapy agents exert their neurotoxic effects.  Unmyelinated C fibers and myelinated 
Aδ fibers can detect a variety of stimulus that can be both physical and chemical in nature.  
Although primary afferent neurons have their cell bodies in the dorsal root ganglion and transmit 
information from peripheral tissue to the spinal cord, unmyelinated C and myelinated Aδ fibers 
only project to superficial layers of the spinal cord.  Primary afferent sensory fibers can detect 
nonnoxious sensations, such as light touch, vibration, and proprioceptive stimuli, whereas 
unmyelinated C and myelinated Aδ fibers can detect noxious chemical, thermal, and mechanical 
stimuli.  It is also postulated that the unmyelinated C and myelinated Aδ fibers generate the pain 
that is caused by antitumor therapies, such as chemotherapies that include taxanes and platinum-
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based compounds, causing chemotherapy-induced peripheral neuropathy (Argyriou et al., 2012; 
Mantyh, 2006). 
Previous research supports this hypothesized mechanism of the neurotoxic effects of 
chemotherapy on the nerves, as cancer patients diagnosed with CIPN have various sensory signs 
and symptoms that start with paresthesia and numbness in the hands and vibratory perception, 
along with disabling pain, which suggests involvement of small, unmyelinated nerve fibers 
(Hilkens et al., 1997).  However, Visovsky and Daly (2004) found no effect on  deep tendon 
reflex  using Babinski’s reflex hammer, which suggests that the type Ia, type Ib, and type 2 
afferent nerves that innervate Golgi tendon organs and muscles spindles and their corresponding 
reflex mechanisms are intact.  This is a significant observation because it is proposed in the 
literature that these three reflex mechanisms are most responsible for mediating gait (Dietz, 
2002).   
Conversely, a more recent study by Kneis and colleagues (2015) found that cancer 
patients who received taxane chemotherapy demonstrated prolonged H-reflex latency, as well as 
changes in H-reflex sensitivity associated with modulated spinal excitability.  These findings 
suggest that chemotherapy agents may have a neurotoxic effect on the Ia afferent fibers of 
muscle spindle and Golgi tendon organs that are part of the monosynaptic reflex arcs.  The 
authors also noted that cancer patients with CIPN displayed increased postural sway.  However, 
the study did not find a correlation between H-reflex latency and center-of-pressure sway path.  
Therefore, although evidence supports that unmyelinated C and myelinated Aδ fibers may 
experience a neurotoxic effect due to chemotherapy, and possibly even type Ia afferent fibers part 
of reflex arcs, the primary fibers that experience the neurotoxic effect of thermotherapy may not 
be prime gait mediators, which may explain why there were no significant differences found in 
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spatial and temporal gait parameters other than velocity between those with CIPN and their 
healthy and morphologically matched controls (Kneis et al., 2015).  
A second explanation for the inconsistencies in the present study with previous research 
is that although unmyelinated C and myelinated Aδ fibers may experience a neurotoxic effect 
due to chemotherapy, individuals may develop compensatory behaviors due to the loss of 
sensory input caused by CIPN.  Gait is the result of afferent information from visual, vestibular, 
and proprioceptive systems.  These three system do not operate independently; the body uses 
somatosensory information from all bodily sources in order to shape functional movement.  
When the contribution of somatosensory information is attenuated, or lost, such as in the case of 
peripheral neuropathy, the vestibular system provides a greater contribution to posture and 
balance (Horak & Hlavacka, 2001; Simoneau et al., 1995).  
Mergner, Huber, and Becker (1997) postulated that vestibular information descends down 
body segments where it meets and fuses with ascending somatosensory information, combining 
to provide coordinates as to where the body is in space (Mergner & Rosemeier, 1998).  Thus, 
when somatosensory information is lessened, the body still receives vestibular sensory 
information to regulate body movement.  The vestibular system may primarily mediate the trunk 
during gait, which is important to note because the trunk may have a greater influence on gait 
stability then lower body segments because the trunk has a larger body mass.  Therefore, it needs 
a greater amount of stability while walking (Creath, Kiemel, Horak, & Jeka, 2008; Deshpande & 
Zhang, 2014).  Furthermore, the vestibular system may be a greater mediator of stability during 
gait.  Thus, although CIPN patients may have attenuate somatosensory afferent feedback, more 
noticeable changes in spatiotemporal gait parameters other than gait velocity were not found due 
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to the intact vestibular information that is critical for trunk control and walking accuracy 
(Deshpande & Zhang, 2014). 
Although previous research has established the importance of afferent feedback for the 
mediation of gait, the extent of the mediation remains unknown.  Decreased gait velocities may 
not only be due to the neurotoxic effect of the chemotherapy agents but also due to the presence 
of pain.  Individuals with CIPN commonly report symptoms that include burning, muscle aches, 
sensitivity to cold, and feelings of “walking on hot coals” or “sandpaper on the bottom of your 
feet”; cancer patients experiencing CIPN often report varying degrees of pain (Tofthagen, 2010; 
p. E25).  The presence of pain alone is associated with a decrease in walking velocity; a recent 
study that evaluated Gait parameters in individuals with foot pain related to gout found that those 
individuals with gout-related foot pain walked significantly slower (Stewart, 2016).  A study by 
van den Hoorn, Hug, Hodges, Bruijn, and van Dieën (2015) investigated if nociceptive 
stimulation and induced pain affect gait stability.  Previous research suggests that 
musculoskeletal pain is associated with fall risk and has a negative impact on stability (Asai, 
Misu, Sawa, Doi, & Yamada, 2015; de Zwart et al., 2015; Kitayuguchi, Kamada, Okada, 
Kamioka, & Mutoh, 2015; Ross, Mavor, Brown, & Graham, 2015).   
It is hypothesized that individuals who are experiencing pain will adapt their motor 
program to protect injured tissues.  The adaptations may increase joint stability because the 
muscles are less responsive in order to reduce pain.  For example, if pain is presence in the calf, 
the calf muscle may not be as responsive, as indicated by a decrease in contractions, resulting in 
a decrease in the range of motion the ankle joint may undergo during gait (Hodges & Tucker, 
2011; Lund, Donga, Widmer, & Stohler, 2011; van Dieën, Selen, & Cholewicki, 2003).  The 
combination of increased joint stiffness, decreased responsiveness of the tissues, and the 
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presence of impaired nociceptive afferent fibers, with decreasing proprioceptive acuity and the 
inability to regulate force, may result in a decrease in stability (Brumagne, Cordo, Lysens, 
Verschueren, & Swinnen, 2000; Descarreaux, Blouin, & Teasdale, 2005; Hodges et al., 2011; 
Lee, Cholewicki, Reeves, Zazulak, & Mysliwiec, 2010; Matre, Arendt-Nielsen, & Knardahl, 
2002; Salomoni, Ejaz, Laursen, & Graven-Nielsen, 2013; van den Hoorn, Bruijn, Meijer, 
Hodges, & van Dieën, 2012).  
Van den Hoorn and colleagues (2015) found that nociceptive irritation of the calf and 
back muscled decrease gait stability at low walking speed.  Greater effects were seen in the calf 
than in the low back, which puts forth the idea that the gait adaptations may depend on the 
specific muscle.  The findings of van den Hoorn and colleagues that the presence of pain can 
affect gait stability at lower walking speeds and that the specific muscle affected also plays a 
critical role are important to note because cancer patients with CIPN, as well as individuals with 
diabetic peripheral neuropathy (DPN), often report pain in their lower legs, specifically their feet 
and calves (Tofthagen, 2010).  Thus the presence of pain in the lower extremities by individuals 
with CIPN is significant because the decrease in gait speed could be caused not by the decrease 
in afferent feedback but simply by the presence of pain because it is suggested that individuals 
who are experiencing pain may undergo motor adaptations to protect the painful/injured tissues, 
resulting in a decrease in gait velocity (Hodges & Tucker, 2011; Lund et al., 2011; van Dieën et 
al., 2003). 
Lastly, the slower walking velocities may not be due to the attenuated afferent feedback 
or presence of pain but may be due to a deconditioning effect experienced by cancer patients that 
has been documented to occur while undergoing treatment for cancer.   
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A stable and successful gait that allows individuals to safely navigate their environment 
requires an appropriate amount of muscular strength and joint range of motion (Neumann, 2002; 
Shumway-Cook & Woollacott, 2012).  Chemotherapy and radiation therapy may often cause 
muscle atrophy and muscles weakness (Mustian et al., 2009).  Certain chemotherapy agents may 
cause pulmonary fibrosis and abnormal development of pulmonary tissue, resulting in coughing, 
dyspnea, fatigue, and overall decreased functional capacity (Schneider et al., 2003).  It is 
estimated that 30% of cancer survivors will decrease their physical activity levels upon receiving 
a cancer diagnosis, and up to 70% of cancer survivors do not meet the U.S national 
recommendations for exercises and physical activity (Blanchard, Courneya, & Stein, 2008; 
Blanchard, Denniston, & Backer, 2003).  Thus, due to the decreased amount of physical activity 
and the effects of cancer therapies, many cancer patients experience a deconditioning effect, 
which could cause slower gait velocities and decrease step length.  Ko, Stenholm, Metter, and 
Ferrucci (2012) found that a decrease in gait speed was associated with decreases in range of 
motion within the hip, knee, and ankle.  Ko and colleagues (2012) also found that a slower gait 
velocity was also associated with a decrease in maximum isokinetic knee extensor strength, 
suggesting that muscle strength is a contributing factor in gait velocity.  Thus, as the body 
becomes weaker and stiffer, as indicated by decrease joint range of motion, gait will also become 
slower.  This association between gait and a deconditioned body may also explain the slower gait 
in those with CIPN because the participants in the present study were nonexercisers as defined 
by the inclusion criteria, which required that they not participate in more than 150 min of regular 
physical activity per week.  The chemotherapy treatments undergone by those with CIPN may 
have caused a deconditioning effect, resulting in loss of muscle strength that may also have been 
a contributing factor to the significantly slower walking velocities.  However, the present study 
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did not evaluate and quantify this possible deconditioning effect and compare the physical status 






















EFFECTS OF CIPN ON GAIT AND FALL RISK                                                                    94  
Chapter V1 
SUMMARY AND CONCLUSIONS 
As improvements continue to be made in screening measures and treatment options, the 
number of cancer survivors will increase.  However, many cancer survivors will face long-term 
physical health effects and functional impairments due to chemotherapy-induced peripheral 
neuropathy (CIPN).  Neuropathy is associated with postural and functional impairments.  In 
cancer patients with CIPN, impairments may manifest as gait or balance disorders, which may be 
linked to higher rates of falling, limiting activities of daily living.  However, the exact nature in 
which CIPN affects the spatiotemporal mechanism of gait remains largely unknown (Kneis et al., 
2015).   
The results of this study indicate that cancer patients with CIPN displayed a slower 
walking velocity and shorter step length, resulting in a higher risk of falls, compared to healthy, 
age and morphologically matched controls.  Additional gait patterns, such as step time, base of 
support, swing time, single support time, and double support time, were not significantly 
different.  Also, while the mean TUG score for CIPN patients was not only significantly greater, 
but was also above the clinical fall risk cut off of 10.7 s, indicating fall risk.  Both gait speed and 
step length are key indicators for fall risk; slower gait velocities and shorter step lengths are 
associated with increased fall risk (Espy et al., 2010; Schult et al., 2013; Verghese et al., 2009)  
Despite the findings that gait velocity and step length is significantly reduced in 
individuals with CIPN, there were several limitations to the present study.  First, the presence of 
CIPN was determined by the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4.0, in which patients can simply report numbness and tingling.  Therefore, the extent of 
the damage to peripheral nerves was not quantified.  Secondly, it remains unknown if the cause 
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of decreased gait velocity was due to the neurotoxic effect of the chemotherapy agents on the 
afferent nerve fibers that provide gait mediation or if the decreased gait velocity was due to the 
presence of neuropathic pain, or a combination of both. Lastly, gait velocity may also have been 
slowed due to a deconditioning effect caused by the treatment process.  But this possible 
deconditioning effect was not accounted for in the present study.  
Future research studies should address the limitations of the present study and investigate 
the effect (if any) of the deconditioning caused by chemotherapy treatments on gait velocity.  
Future studies might also investigate the timing during a chemotherapy regimen of taxane or 
oxaliplatin, during which the gait velocity may decrease.  Future research might also investigate 
other chemotherapeutic agents that case CIPN, such as vincristine, and if the same changes in 
gait velocity occur.  
In conclusion, the finding that gait velocities and step length were significantly slower in 
individuals with CIPN, as well as increased risk of falls as assessed by the TUG test, is very 
meaningful because slower gait velocities and shorter step lengths are associated with increased 
fall risk, which was demonstrated by the CIPN participant’s mean TUG score. 
Although this significant association was found, it remains unknown if the cause of the 
decreased gait velocity, shortened step length, and increased risk of falls as assessed by the TUG 
test, was the neurotoxic effect of the chemotherapy agents on the afferent nerve fibers that 
provide gait mediation or if the decreased gait velocity was due to the presence of neuropathic 
pain or a deconditioning effect caused by the treatment process. Nevertheless, the study findings 
aid in understanding the effects of chemotherapy-induced peripheral neuropathy on 
spatiotemporal gait parameters in cancer patients post chemotherapy drug treatment and assist in 
addressing functional limitations in CIPN patients 
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